var title_f12_8_12416="Proximal humeral physis anatomy";
var content_f12_8_12416=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The anatomy of the proximal humerus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 380px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The solid blue line corresponds to the appearance of the physis on radiograph. The dotted line provides the outer limit&nbsp;of the shoulder joint capsule.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sarwark JF, King EC, Luhmann SJ. Proximal humerus, scalpula, and clavicle. In: Rockwood and Wilkins' Fractures in Children, 6th edition, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_8_12416=[""].join("\n");
var outline_f12_8_12416=null;
var title_f12_8_12417="Severe bronchiectasis CT";
var content_f12_8_12417=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69987&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69987&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Severe bronchiectasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 332px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Severe bronchiectasis in a destroyed right lung as a sequel of necrotizing pneumonia. There is complete cicatrization atelectasis of the right lung with a cardiomediastinal shift to the right. The right lung is permeated by small cystic structures consistent with cystic bronchiectasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_8_12417=[""].join("\n");
var outline_f12_8_12417=null;
var title_f12_8_12418="Acute histoplasmosis chest x-ray";
var content_f12_8_12418=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F69279&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F69279&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute histoplasmosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 372px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest x-ray from a patient with acute pulmonary histoplasmosis shows enlargement of right hilar lymph nodes (red arrow) and a patchy right upper lobe infiltrate (blue arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joseph Wheat, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_8_12418=[""].join("\n");
var outline_f12_8_12418=null;
var title_f12_8_12419="Measures isovolumic relaxation";
var content_f12_8_12419=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69433&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69433&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Measures of isovolumic relaxation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 350px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_8_12419=[""].join("\n");
var outline_f12_8_12419=null;
var title_f12_8_12420="Mannose-binding lectin";
var content_f12_8_12420=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mannose-binding lectin",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/8/12420/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/8/12420/contributors\">",
"     Maarten W Bronkhorst, MD, FEBS, FRCS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/8/12420/contributors\">",
"     Lee H Bouwman, MD, PhD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/8/12420/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/8/12420/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/8/12420/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/8/12420/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/8/12420/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mannose-binding lectin (MBL), also known as mannan-binding protein (MBP), is a protein that specifically binds or crosslinks carbohydrates. Lectins are involved in complement activation via the lectin pathway. The complement system provides immediate defense against infection and has proinflammatory effects; it is considered part of both the innate and adaptive immune systems.",
"   </p>",
"   <p>",
"    This topic will discuss the genetic defects and polymorphisms of the MBL2 gene and the function of the MBL protein. The diagnosis of MBL deficiency, diseases associated with both low and high levels of MBL, and other aspects of the complement system are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/14/19690?source=see_link\">",
"     \"Mannose-binding lectin deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11190?source=see_link\">",
"     \"Complement pathways\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10647?source=see_link\">",
"     \"Overview and clinical assessment of the complement system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10854?source=see_link\">",
"     \"Regulators and receptors of the complement system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THE MBL GENE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many animals there are two MBL genes, MBL1 and MBL2, that code for a functional product. However, in humans the MBL1 gene, MBL1P1, is a pseudogene (ie, it does not produce a functional protein) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12420/abstract/1\">",
"     1",
"    </a>",
"    ]. The two MBL genes are most likely the result of a gene-duplication event [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12420/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The gene encoding functional MBL in humans, MBL2, is located on the long arm of chromosome 10 (10q11.2-q21) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12420/abstract/3\">",
"     3",
"    </a>",
"    ]. The MBL2 gene is also known as collectin subfamily member 2 or COLEC2 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12420/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The human MBL protein is encoded by four exons. The MBL2 gene also contains an extra exon about 1 kb upstream of exon 1, named exon 0, which may initiate transcription of the MBL2 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12420/abstract/5\">",
"     5",
"    </a>",
"    ]. Gene expression is primarily regulated by several consensus elements in the promoter region [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12420/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The normal allele is called allele A. To date, three point mutations have been identified, all in exon 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12420/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allele B &mdash; Codon 54, GGC to GAC (Gly_Asp)",
"     </li>",
"     <li>",
"      Allele C &mdash; Codon 57, GGA to GAA (Gly_Glu)",
"     </li>",
"     <li>",
"      Allele D &mdash; Codon 52, CGT to TGT (Arg_Cys)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The wild-type is denoted MBL2 genotype",
"    <span class=\"nowrap\">",
"     A/A",
"    </span>",
"    and the pooled MBL variants (B, C, and D) are denoted MBL2 genotype",
"    <span class=\"nowrap\">",
"     0/0",
"    </span>",
"    (where the \"0\" stands for one of the variant alleles).",
"   </p>",
"   <p>",
"    The MBL variant proteins are unstable and probably have a shorter half-life in the circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12420/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. In addition, all mutations in exon 1 interfere with the formation of higher order oligomers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12420/abstract/12\">",
"     12",
"    </a>",
"    ]. The variant MBL has a lower molecular weight and does not bind mannan efficiently nor activate complement. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'The MBL protein'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition to the three mutations in exon 1, there are several other polymorphic sites located in the MBL promoter region that are associated with decreased MBL serum concentration. These include single nucleotide polymorphisms (SNPs) located at position -550",
"    <span class=\"nowrap\">",
"     (H/L",
"    </span>",
"    variant), and -221",
"    <span class=\"nowrap\">",
"     (Y/X",
"    </span>",
"    variant), both G to C nucleotide substitutions. Another polymorphic site is located at position +4 of the 5'-untranslated portion of the MBL2 gene",
"    <span class=\"nowrap\">",
"     (P/Q",
"    </span>",
"    variant, C to T). The promoter haplotypes, HY, LY, and LX are associated with high, medium, and low levels of MBL serum concentrations, respectively. In addition, a low producing LX haplotype in the homozygous state seems to down-regulate the basal expression of MBL as effectively as a single structural variant [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12420/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The molecular mechanisms resulting in different MBL serum levels associated with the MBL2 gene promoter types have not yet been elucidated [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12420/abstract/12,13,15\">",
"     12,13,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Four common haplotypes have been identified on a normal A chromosomal background: HYPA, LYPA, LYQA, and LXPA, with high, high-intermediate, intermediate, and low promoter activity. The variant alleles are associated with HYPD, LYPB, and LYQC [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12420/abstract/4,13,15\">",
"     4,13,15",
"    </a>",
"    ]. Other haplotypes have been described, but are rare due to linkage disequilibrium [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12420/abstract/16\">",
"     16",
"    </a>",
"    ]. The serum level of MBL is strongly associated with the individual's haplotype.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     THE MBL PROTEIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal lectins that are dependent upon the presence of calcium ions are named C-type lectins. Members of the C-type family include selectins, hepatic type II receptors, type I transmembrane proteins, collectins (collagen-like lectins), and lecticans.",
"   </p>",
"   <p>",
"    The collectins include three serum proteins (mannose-binding lectin, bovine conglutinin, and bovine collectin 43) and two lung surfactant proteins (SP-A and SP-D) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12420/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. These proteins play important roles in innate immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12420/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16986?source=see_link&amp;anchor=H9421023#H9421023\">",
"     \"An overview of the innate immune system\", section on 'Collectins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The MBL protein consists of multimers of an identical 25 kDa polypeptide chain synthesized by the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12420/abstract/4\">",
"     4",
"    </a>",
"    ]. Three polypeptide chains form a triple helix within the collagen-like region. These structural subunits form covalent oligomers via disulfide bonds at the N-terminal end. MBL in serum primarily consists of trimers and tetramers of 9 and 12 polypeptides respectively, but the oligomers can range from dimers to hexamers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12420/abstract/4\">",
"     4",
"    </a>",
"    ]. These higher-order oligomers are necessary for the function of MBL and the interaction with MBL-associated serine proteases (MASPs) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12420/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MBL binds carbohydrates in the presence of Ca2+ through the C-terminal carbohydrate-recognition domain (CRD) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12420/abstract/17,18,25\">",
"     17,18,25",
"    </a>",
"    ]. The CRD is able to form bonds with hydroxyl groups on specific ligands, including mannose, N-acetyl-d-glucosamine (GlcNAc), N-acetyl-mannosamine, fucose, and glucose. These carbohydrates are found on pathologic microorganisms, including bacteria, fungi, parasitic protozoans, and viruses. CRD also recognizes molecular structures of dying host cells, including nucleic acids and the metalloproteases, meprin-alpha and -beta [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12420/abstract/4\">",
"     4",
"    </a>",
"    ]. Carbohydrates that are found on mammalian glycoproteins, such as D-galactose and sialic acid, have no affinity for MBL. Thus, MBL is able to bind to microbes or unwanted material and trigger the activation of the lectin pathway, but it avoids recognition of self.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     THE LECTIN PATHWAY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complement system can be activated through three pathways: the classical pathway, the alternative pathway, and the lectin pathway (",
"    <a class=\"graphic graphic_figure graphicRef60513 \" href=\"UTD.htm?34/45/35550\">",
"     figure 1",
"    </a>",
"    ). The lectin pathway has an activation scheme similar to that of the classical pathway, but lectins substitute for antibodies and an associated protease replaces C1. MBL and related collectins bind sugar residues on the microbial surface; their associated proteases (MASPs) subsequently cleave C4 and C2. The complement activation pathways are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11190?source=see_link\">",
"     \"Complement pathways\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MBL DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall, individuals generally benefit from normal levels of MBL. However, in some cases low levels appear to be advantageous. The association of both decreased and elevated serum levels of MBL, due to different polymorphisms of the MBL2 gene and its promoter, with a variety of diseases is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/14/19690?source=see_link\">",
"     \"Mannose-binding lectin deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mannose-binding lectin (MBL) is a protein involved in complement activation via the lectin pathway (",
"      <a class=\"graphic graphic_figure graphicRef60513 \" href=\"UTD.htm?34/45/35550\">",
"       figure 1",
"      </a>",
"      ). The complement system provides immediate defense against infection and has proinflammatory effects. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'The lectin pathway'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Decreased levels of MBL can result from mutations in the MBL2 gene or its promoter. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'The MBL gene'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      MBL binds to carbohydrates on microbes or unwanted material and triggers the activation of the lectin pathway, but it does not recognize self carbohydrates. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'The MBL protein'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'The lectin pathway'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11190?source=see_link\">",
"       \"Complement pathways\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12420/abstract/1\">",
"      Guo N, Mogues T, Weremowicz S, et al. The human ortholog of rhesus mannose-binding protein-A gene is an expressed pseudogene that localizes to chromosome 10. Mamm Genome 1998; 9:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12420/abstract/2\">",
"      Sastry R, Wang JS, Brown DC, et al. Characterization of murine mannose-binding protein genes Mbl1 and Mbl2 reveals features common to other collectin genes. Mamm Genome 1995; 6:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12420/abstract/3\">",
"      Sastry K, Herman GA, Day L, et al. The human mannose-binding protein gene. Exon structure reveals its evolutionary relationship to a human pulmonary surfactant gene and localization to chromosome 10. J Exp Med 1989; 170:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12420/abstract/4\">",
"      Garred P. Mannose-binding lectin genetics: from A to Z. Biochem Soc Trans 2008; 36:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12420/abstract/5\">",
"      Naito H, Ikeda A, Hasegawa K, et al. Characterization of human serum mannan-binding protein promoter. J Biochem 1999; 126:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12420/abstract/6\">",
"      Sumiya M, Super M, Tabona P, et al. Molecular basis of opsonic defect in immunodeficient children. Lancet 1991; 337:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12420/abstract/7\">",
"      Lipscombe RJ, Sumiya M, Hill AV, et al. High frequencies in African and non-African populations of independent mutations in the mannose binding protein gene. Hum Mol Genet 1992; 1:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12420/abstract/8\">",
"      Madsen HO, Garred P, Kurtzhals JA, et al. A new frequent allele is the missing link in the structural polymorphism of the human mannan-binding protein. Immunogenetics 1994; 40:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12420/abstract/9\">",
"      Larsen F, Madsen HO, Sim RB, et al. Disease-associated mutations in human mannose-binding lectin compromise oligomerization and activity of the final protein. J Biol Chem 2004; 279:21302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12420/abstract/10\">",
"      Matsushita M, Ezekowitz RA, Fujita T. The Gly-54--&gt;Asp allelic form of human mannose-binding protein (MBP) fails to bind MBP-associated serine protease. Biochem J 1995; 311 ( Pt 3):1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12420/abstract/11\">",
"      Naito H, Ma Y, Uemura K, et al. Metabolic properties of normal and mutant mannan-binding proteins in mouse plasma. Biochem Biophys Res Commun 1999; 256:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12420/abstract/12\">",
"      Garred P, Larsen F, Madsen HO, Koch C. Mannose-binding lectin deficiency--revisited. Mol Immunol 2003; 40:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12420/abstract/13\">",
"      Madsen HO, Garred P, Thiel S, et al. Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol 1995; 155:3013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12420/abstract/14\">",
"      Garred P, Honor&eacute; C, Ma YJ, et al. MBL2, FCN1, FCN2 and FCN3-The genes behind the initiation of the lectin pathway of complement. Mol Immunol 2009; 46:2737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12420/abstract/15\">",
"      Madsen HO, Satz ML, Hogh B, et al. Different molecular events result in low protein levels of mannan-binding lectin in populations from southeast Africa and South America. J Immunol 1998; 161:3169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12420/abstract/16\">",
"      Boldt AB, Petzl-Erler ML. A new strategy for mannose-binding lectin gene haplotyping. Hum Mutat 2002; 19:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12420/abstract/17\">",
"      Drickamer K. Engineering galactose-binding activity into a C-type mannose-binding protein. Nature 1992; 360:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12420/abstract/18\">",
"      Weis WI, Drickamer K, Hendrickson WA. Structure of a C-type mannose-binding protein complexed with an oligosaccharide. Nature 1992; 360:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12420/abstract/19\">",
"      Kimura T, Imai Y, Irimura T. Calcium-dependent conformation of a mouse macrophage calcium-type lectin. Carbohydrate binding activity is stabilized by an antibody specific for a calcium-dependent epitope. J Biol Chem 1995; 270:16056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12420/abstract/20\">",
"      Lu J. Collectins: collectors of microorganisms for the innate immune system. Bioessays 1997; 19:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12420/abstract/21\">",
"      Fujita T. Evolution of the lectin-complement pathway and its role in innate immunity. Nat Rev Immunol 2002; 2:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12420/abstract/22\">",
"      Fujita T, Matsushita M, Endo Y. The lectin-complement pathway--its role in innate immunity and evolution. Immunol Rev 2004; 198:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12420/abstract/23\">",
"      Thielens NM, Cseh S, Thiel S, et al. Interaction properties of human mannan-binding lectin (MBL)-associated serine proteases-1 and -2, MBL-associated protein 19, and MBL. J Immunol 2001; 166:5068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12420/abstract/24\">",
"      Wallis R, Drickamer K. Molecular determinants of oligomer formation and complement fixation in mannose-binding proteins. J Biol Chem 1999; 274:3580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12420/abstract/25\">",
"      Sheriff S, Chang CY, Ezekowitz RA. Human mannose-binding protein carbohydrate recognition domain trimerizes through a triple alpha-helical coiled-coil. Nat Struct Biol 1994; 1:789.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3934 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-197.136.42.3-3C9D172F08-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_8_12420=[""].join("\n");
var outline_f12_8_12420=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THE MBL GENE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      THE MBL PROTEIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      THE LECTIN PATHWAY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MBL DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3934\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3934|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/45/35550\" title=\"figure 1\">",
"      Pathways of complement activation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16986?source=related_link\">",
"      An overview of the innate immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11190?source=related_link\">",
"      Complement pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/14/19690?source=related_link\">",
"      Mannose-binding lectin deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10647?source=related_link\">",
"      Overview and clinical assessment of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10854?source=related_link\">",
"      Regulators and receptors of the complement system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_8_12421="Clarithromycin: Patient drug information";
var content_f12_8_12421=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Clarithromycin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     see \"Clarithromycin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"     see \"Clarithromycin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F152372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Biaxin&reg;;",
"     </li>",
"     <li>",
"      Biaxin&reg; XL",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F152373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Clarithromycin&reg;;",
"     </li>",
"     <li>",
"      Ava-Clarithromycin;",
"     </li>",
"     <li>",
"      Biaxin&reg;;",
"     </li>",
"     <li>",
"      Biaxin&reg; XL;",
"     </li>",
"     <li>",
"      Dom-Clarithromycin;",
"     </li>",
"     <li>",
"      Mylan-Clarithromycin;",
"     </li>",
"     <li>",
"      PMS-Clarithromycin;",
"     </li>",
"     <li>",
"      RAN&trade;-Clarithromycin;",
"     </li>",
"     <li>",
"      ratio-Clarithromycin;",
"     </li>",
"     <li>",
"      Riva-Clarithromycin;",
"     </li>",
"     <li>",
"      Sandoz-Clarithromycin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10011265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop infections of the heart for patients with a higher chance of getting an infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to clarithromycin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701012",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If this drug caused liver problems before.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705251",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a long QT on ECG.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703919",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: If you have a narrowing of the GI (gastrointestinal) tract or a bowel block.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698205",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may see the tablet shell in your stool.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696431",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695766",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take liquid (suspension) or tablets with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695777",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take long-acting products with food. Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699462",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (suspension) at room temperature. Throw away any part not used after 2 weeks.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12226 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-A90D1A112B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_8_12421=[""].join("\n");
var outline_f12_8_12421=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152372\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152373\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011265\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011267\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011266\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011271\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011272\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011274\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011269\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011270\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011275\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011276\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=related_link\">",
"      Clarithromycin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=related_link\">",
"      Clarithromycin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_8_12422="Pneumococcal polysaccharide vaccine (23-valent): Drug information";
var content_f12_8_12422=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pneumococcal polysaccharide vaccine (23-valent): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?14/5/14417?source=see_link\">",
"    see \"Pneumococcal polysaccharide vaccine (23-valent): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/12/4294?source=see_link\">",
"    see \"Pneumococcal polysaccharide vaccine (23-valent): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F210866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pneumovax&reg; 23",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F210867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pneumo 23&trade;;",
"     </li>",
"     <li>",
"      Pneumovax&reg; 23",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F210878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vaccine, Inactivated (Bacterial)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F210868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Immunization:",
"     </b>",
"     I.M., SubQ: 0.5 mL as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Primary vaccination:",
"     </i>",
"     Adults 19-64 years with specified underlying medical conditions and all patients at 65 years of age without previous PPSV23 vaccination should receive one dose of PPSV23 (CDC, 59[34], 2010). In patients who are pneumococcal vaccine na&iuml;ve (no previous PCV13 or PPSV23 vaccine), administer a single dose of PCV13 followed by 1 dose of PPSV23 8-weeks later (CDC, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Revaccination:",
"     </i>",
"     Adults 19-64 years with functional or anatomic asplenia, or who are immunocompromised: One revaccination dose &ge;5 years after first dose of PPSV23 (CDC, 59[34], 2010) and &ge;8 weeks after PCV13 (CDC, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F210874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/12/4294?source=see_link\">",
"      see \"Pneumococcal polysaccharide vaccine (23-valent): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     <b>",
"      Immunization:",
"     </b>",
"     Children &ge;2 years: I.M., SubQ: 0.5 mL as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Primary vaccination:",
"     </i>",
"     Children with specified underlying medical conditions: One dose of PPSV23 should be given at &ge;2 years of age. Immunization with PCV13 should be completed prior to PPSV23 as recommended. The minimum interval between the last dose of PCV13 and PPSV23 is 8 weeks (CDC, 59[11] 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Revaccination:",
"     </i>",
"     Children with functional or anatomic asplenia, or who are immunocompromised: One revaccination dose &ge;5 years after the first dose of PPSV23. Revaccination of immunocompetent individuals is generally not recommended (CDC, 59[11] 2010).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F210869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Immunization:",
"     </b>",
"     I.M., SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Primary immunization:",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Revaccination:",
"     </i>",
"     &ge;65 years: One revaccination dose if &ge;5 years after first dose of PPSV23 and if &lt;65 years of age at the time of the initial vaccination (for any indication). Immunocompetent adults who received primary vaccination at &ge;65 years do not need to be revaccinated (CDC, 59[34], 2010; CDC 2012).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F210854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Pneumovax&reg; 23: 25 mcg each of 23 capsular polysaccharide isolates/0.5 mL (0.5 mL, 2.5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F210842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F210857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not inject I.V.; avoid intradermal administration (may cause severe local reactions); administer SubQ or I.M. (deltoid muscle or lateral midthigh)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     For patients at risk of hemorrhage following intramuscular injection, the ACIP recommends &ldquo;it should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23 gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection.&rdquo; Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Antipyretics have not been shown to prevent febrile seizures. Antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Simultaneous administration of vaccines helps ensure the patients will be fully vaccinated by the appropriate age. Simultaneous administration of vaccines is defined as administering &gt;1 vaccine on the same day at different anatomic sites. Separate vaccines should not be combined in the same syringe unless indicated by product specific labeling. Separate needles and syringes should be used for each injection. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible. Adolescents and adults should be vaccinated while seated or lying down. In general, preterm infants should be vaccinated at the same chronological age as full-term infants (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F210855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immunization against pneumococcal disease caused by serotypes included in the vaccine. Routine vaccination is recommended for persons &ge;50 years of age and persons &ge;2 years in certain situations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination for patients with the following underlying medical conditions (CDC, 59[34], 2010; CDC, 59[11], 2010; CDC, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Children &ge;2 years of age and adults 19-64 years",
"     </b>",
"     with functional or anatomic asplenia, including sickle cell disease or other hemoglobinopathies, congenital or acquired asplenia, splenic dysfunction, or splenectomy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Immunocompetent children &ge;2 years of age",
"     </b>",
"     with chronic heart disease (particularly cyanotic congenital heart disease and heart failure), chronic lung disease (including asthma if treated with high dose corticosteroids), diabetes, cerebrospinal fluid leaks, or cochlear implants",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Immunocompetent adults 19-64 years",
"     </b>",
"     with chronic heart disease (including heart failure and cardiomyopathies; excluding hypertension), chronic lung disease (including COPD, emphysema, and asthma), diabetes, cerebrospinal fluid leaks, cochlear implants, alcoholism, chronic liver disease, cirrhosis, and cigarette smokers",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Immunocompromised children &ge;2 years of age and adults 19-64 years",
"     </b>",
"     with congenital or acquired immunodeficiency (includes B or T cell deficiency, compliment deficiencies and phagocytic disorders; excludes chronic granulomatous disease), HIV infection, chronic renal failure, nephrotic syndrome, leukemia, lymphoma, Hodgkin disease, generalized malignancies, solid organ transplant, multiple myeloma, or other diseases requiring immunosuppressive drugs (including long-term systemic corticosteroids and radiation therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      All adults &ge;65 years of age",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7914139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Pneumococcal 23-Valent Polysaccharide Vaccine (Pneumovax&reg; 23) may be confused with Pneumococcal 7-Valent Conjugate Vaccine (Prevnar&reg;) or with Pneumococcal 13-Valent Conjugate Vaccine (Prevnar 13&reg;)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F210876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Chills, Guillain-Barr&eacute; syndrome, fever &le;102&deg;F*, fever &gt;102&deg;F, headache, malaise, pain, radiculoneuropathy, seizure (febrile)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Angioneurotic edema, cellulitis, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hematologic: Hemolytic anemia (in patients with other hematologic disorders), leukocytosis, thrombocytopenia (in patients with stabilized ITP)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Local: Injection site reaction* (erythema, induration, swelling, soreness, warmth); peripheral edema in injected extremity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, arthritis, limb mobility decreased, myalgia, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Anaphylactoid reaction, C-reactive protein increased, lymphadenitis, lymphadenopathy, serum sickness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     *Reactions most commonly reported in clinical trials.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F210859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pneumococcal vaccine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F210846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1:1000) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Syncope: Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Immunization should be delayed during the course of an acute febrile illness or other active infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with severely compromised cardiovascular function where a systemic reaction may pose a significant risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HIV: Patients with HIV should be vaccinated as soon as possible (following confirmation of the diagnosis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with severe pulmonary disease where a systemic reaction may pose a significant risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Splenectomy: Patients who will undergo splenectomy should also be vaccinated at least 2 weeks prior to surgery, if possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombocytopenia purpura: May cause relapse in patients with stable idiopathic thrombocytopenia purpura.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaccines:  In order to maximize vaccination rates, the ACIP recommends simultaneous administration of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist.  If a person has not received any pneumococcal vaccine or if pneumococcal vaccination status is unknown, PPSV23 should be administered as indicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered immunocompetence: Use with caution in severely immunocompromised patients; patients who will be receiving immunosuppressive therapy (including Hodgkin's disease, cancer chemotherapy, or transplantation) should be vaccinated at least 2 weeks prior to the initiation of therapy. Immune responses may be impaired for several months following intensive immunosuppressive therapy (up to 2 years in Hodgkin's disease patients). In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cochlear implants: Patients who will undergo cochlear implant placement should be vaccinated at least 2 weeks prior to surgery, if possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Postmarketing reports of adverse effects in the elderly, especially those with comorbidities, have been significant enough to require hospitalization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F210849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zoster Vaccine: Pneumococcal Polysaccharide Vaccine (Polyvalent) may diminish the therapeutic effect of Zoster Vaccine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F210851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F210862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Vaccination should be considered in pregnant women at high risk for infection. Inactivated vaccines have not been shown to cause increased risks to the fetus (CDC, 2011)",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F621808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F11569675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inactivated vaccines do not affect the safety of breast-feeding for the mother or the infant. Breast-feeding infants should be vaccinated according to the recommended schedules (CDC,  2011).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection",
"     </b>",
"     (Pneumovax 23 Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mcg/0.5 mL (0.5 mL): $76.16",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6873951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Moniarix (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Pneumo 23 (AR, AT, BE, BG, BR, CL, CN, CO, CR, CZ, DO, EC, EE, ES, FR, GT, HK, HN, ID, IN, IT, MY, NZ, PA, PE, PH, PK, PL, PY, SE, SG, SV, TH, TR, TW, UY);",
"     </li>",
"     <li>",
"      Pneumo 23 Imovax (IL);",
"     </li>",
"     <li>",
"      Pneumo Novum (DK);",
"     </li>",
"     <li>",
"      Pneumovax (CL, JP, SE, SG);",
"     </li>",
"     <li>",
"      Pneumovax 23 (AR, AU, CH, HK, NL, PH, TW);",
"     </li>",
"     <li>",
"      Pneumovax II (GB, IE);",
"     </li>",
"     <li>",
"      Pnu-Imune 23 (GR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F210845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Although there are more than 80 known pneumococcal capsular types, pneumococcal disease is mainly caused by only a few types of pneumococci. Pneumococcal vaccine contains capsular polysaccharides of 23 pneumococcal types of",
"     <i>",
"      Streptococcal pneumoniae",
"     </i>",
"     which represent at least 85% to 90% of pneumococcal disease isolates in the United States. The 23 capsular pneumococcal vaccine contains purified capsular polysaccharides of pneumococcal types 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F,  and 33F.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Prevention of Pneumococcal Disease Among Infants and Children - Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine - Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-11):1-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/8/12422/abstract-text/21150868/pubmed\" id=\"21150868\" target=\"_blank\">",
"        21150868",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/8/12422/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Syncope After Vaccination -- United States, January 2005-July 2007,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 57(17):457-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/8/12422/abstract-text/18451756/pubmed\" id=\"18451756\" target=\"_blank\">",
"        18451756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Updated Recommendations for Prevention of Invasive Pneumococcal Disease Among Adults Using the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23),&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(34):1102-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/8/12422/abstract-text/20814406/pubmed\" id=\"20814406\" target=\"_blank\">",
"        20814406",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults With Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2012, 61:816-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/8/12422/abstract-text/23051612/pubmed\" id=\"23051612\" target=\"_blank\">",
"        23051612",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davidson M, Bulkow LR, Grabman J, et al, &ldquo;Immunogenicity of Pneumococcal Revaccination in Patients With Chronic Disease,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1994, 154(19):2209-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/8/12422/abstract-text/7944842/pubmed\" id=\"7944842\" target=\"_blank\">",
"        7944842",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gardner P and Schaffner W, &ldquo;Immunization of Adults,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 328(17):1252-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/8/12422/abstract-text/8464436/pubmed\" id=\"8464436\" target=\"_blank\">",
"        8464436",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/8/12422/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, &ldquo;Febrile seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008,  121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/8/12422/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9784 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-78FC411DA4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_8_12422=[""].join("\n");
var outline_f12_8_12422=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210866\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210867\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210878\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210868\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210874\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210869\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210854\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210842\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210857\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210855\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7914139\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210876\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210859\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210846\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299892\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210849\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210851\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210862\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F621808\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11569675\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323702\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6873951\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038770\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210845\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9784\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9784|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/5/14417?source=related_link\">",
"      Pneumococcal polysaccharide vaccine (23-valent): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/12/4294?source=related_link\">",
"      Pneumococcal polysaccharide vaccine (23-valent): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_8_12423="Ibandronate: Drug information";
var content_f12_8_12423=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ibandronate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/62/5094?source=see_link\">",
"    see \"Ibandronate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F10911787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Review of Long-term Bisphosphonate Efficacy for Osteoporosis",
"     </span>",
"     <span class=\"collapsible-date\">",
"      May 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       In response to serious postmarketing adverse reactions, including atypical femur fractures, osteonecrosis of the jaw, and esophageal cancer, and a paucity of long-term efficacy data, the FDA conducted a systematic review of long-term bisphosphonate therapy for osteoporosis. To date, randomized controlled trials have shown that bisphosphonate therapy is effective in preventing fractures in trials of 3- to 4-years duration. Therefore, to examine long-term efficacy, three long-term extension trials (involving postmenopausal women) ranging in a duration of treatment from 6-10 years were used in the FDA&rsquo;s analysis. Based on the available long-term clinical trial data, the FDA was unable to identify subgroups of patients who are more likely to benefit from therapy beyond 3-5 years. Continuation of treatment should be based on individual assessment of risks, benefits, and preferences of patients and their physicians.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Until further data are available, the data suggests patients at low risk for fracture (eg, younger patients without a fracture history and bone mineral density [BMD] approaching normal) may be good candidates for discontinuation of therapy after 3-5 years. Patients at increased risk, such as older patients with a history of fracture and a BMD in the osteoporotic range, may benefit from continued therapy.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further investigation into the risks and benefits of long-term therapy, the usefulness of markers of bone turnover or BMD in determining duration or interruption of therapy, and surveillance or fracture risk after therapy discontinuation are needed.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For additional information, please refer to file://www.nejm.org/doi/pdf/10.1056/NEJMp1202619.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F181336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Boniva&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F181350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Bisphosphonate Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F181338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Postmenopausal osteoporosis (treatment):",
"     </b>",
"     Patients should receive supplemental calcium and vitamin D if dietary intake is inadequate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: 150 mg once a month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: 3 mg every 3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Postmenopausal osteoporosis (prevention):",
"     </b>",
"     Patients should receive supplemental calcium and vitamin D if dietary intake is inadequate: Oral: 150 mg once a month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypercalcemia of malignancy (unlabeled use):",
"     </b>",
"     I.V.: 2-6 mg over 1-2 hours (Pecherstorfer, 2003; Ralston, 1997)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Metastatic bone disease due to breast cancer (unlabeled use):",
"     </b>",
"     I.V.: 6 mg every 3-4 weeks (Diel, 2004)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F181339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F181340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Osteoporosis: Oral, I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Use not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oncologic uses (unlabeled): I.V.: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: 2 mg every 3-4 weeks (von Moos, 2005)",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F181341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F181317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Boniva&reg;: 1 mg/mL (3 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 150 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Boniva&reg;: 150 mg [once-monthly formulation]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F181305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F11441255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Boniva&reg; injection:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM241455.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM241455.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Boniva&reg; tablets:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM241518.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM241518.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F181319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Administer 60 minutes before the first food or drink of the day (other than water) and prior to taking any oral medications or supplements (eg, calcium, antacids, vitamins). Ibandronate should be taken in an upright position with a full glass (6-8 oz) of plain water and the patient should avoid lying down for 60 minutes to minimize the possibility of GI side effects. Mineral water with a high calcium content should be avoided. The tablet should be swallowed whole; do not chew or suck. Do not eat or drink anything (except water) for 60 minutes following administration of ibandronate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Take on the same date each month. In case of a missed dose, do not take two 150 mg tablets within the same week. If the next scheduled dose is 1-7 days away, wait until the next scheduled dose to take the tablet. If the next scheduled dose is &gt;7 days away, take the dose the morning it is remembered, and then resume taking the once-monthly dose on the originally scheduled day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Administer as a 15-30 second bolus. Do not mix with calcium-containing solutions or other drugs. For osteoporosis, do not administer more frequently than every 3 months. Infuse over 1 hour for metastatic bone disease due to breast cancer (Diel, 2004) and over 1-2 hours for hypercalcemia of malignancy (Pecherstorfer, 2003; Ralston, 1997).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F181318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment and prevention of osteoporosis in postmenopausal females",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F181346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypercalcemia of malignancy; reduce bone pain and skeletal complications from metastatic bone disease due to breast cancer",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F181348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Percentages vary based on frequency of administration (daily vs monthly). Unless specified, percentages are reported with oral use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (6% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (4% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension (6% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (3% to 7%), dizziness (1% to 4%), insomnia (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypercholesterolemia (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (5% to 8%), diarrhea (4% to 7%), nausea (5%), constipation (3% to 4%), vomiting (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (2% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase decreased (frequency not defined)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Pain in extremity (1% to 8%), arthralgia (4% to 6%), myalgia (1% to 6%), joint disorder (4%), osteonecrosis of the jaw (4%), weakness (4%), osteoarthritis (localized; 1% to 3%), muscle cramp (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchitis (3% to 10%), pneumonia (6%), pharyngitis/nasopharyngitis (3% to 4%), upper respiratory infection (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Acute phase reaction (I.V. 10%; oral 3% to 9%), infection (4%), flu-like syndrome (1% to 4%), allergic reaction (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Anaphylaxis; angioedema; bronchospasm; diaphyseal femur fracture; esophageal cancer; hypocalcemia; incapacitating bone, joint, or muscle pain; iritis; ocular inflammation; scleritis; subtrochanteric femur fracture; uveitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F181322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ibandronate or any component of the formulation; hypocalcemia; oral tablets are also contraindicated in patients unable to stand or sit upright for at least 60 minutes and in patients with abnormalities of the esophagus which delay esophageal emptying, such as stricture or achalasia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F181307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone fractures: Atypical femur fractures have been reported in patients receiving bisphosphonates for treatment/prevention of osteoporosis. The fractures include subtrochanteric femur (bone just below the hip joint) and diaphyseal femur (long segment of the thigh bone). Some patients experience prodromal pain weeks or months before the fracture occurs. It is unclear if bisphosphonate therapy is the cause for these fractures, although the majority have been reported in patients taking bisphosphonates. Patients receiving long-term (&gt;3-5 years) therapy may be at an increased risk.  Discontinue bisphosphonate therapy in patients who develop a femoral shaft fracture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone/joint/muscle pain: Infrequently, severe (and occasionally debilitating) bone, joint, and/or muscle pain have been reported during bisphosphonate treatment. The onset of pain ranged from a single day to several months. Consider discontinuing therapy in patients who experience severe symptoms; symptoms usually resolve upon discontinuation. Some patients experienced recurrence when rechallenged with same drug or another bisphosphonate; avoid use in patients with a history of these symptoms in association with bisphosphonate therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal mucosa irritation: May cause irritation to upper gastrointestinal mucosa. Esophagitis, dysphagia, esophageal ulcers, esophageal erosions, and esophageal stricture (rare) have been reported with oral bisphosphonates; risk increases in patients unable to comply with dosing instructions. Use with caution in patients with dysphagia, esophageal disease, gastritis, duodenitis, or ulcers (may worsen underlying condition). Discontinue if new or worsening symptoms develop.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypocalcemia: Hypocalcemia has been reported with the use of bisphosphonates. Prior to therapy initiation, hypocalcemia must be corrected; ensure adequate calcium and vitamin D intake.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Osteonecrosis of the jaw (ONJ): ONJ has been reported in patients receiving bisphosphonates. Risk factors include invasive dental procedures (eg, tooth extraction, dental implants, boney surgery); a diagnosis of cancer, with concomitant chemotherapy or corticosteroids; poor oral hygiene, ill-fitting dentures; and comorbid disorders (anemia, coagulopathy, infection, pre-existing dental disease). Most reported cases occurred after I.V. bisphosphonate therapy; however, cases have been reported following oral therapy. A dental exam and preventative dentistry should be performed prior to placing patients with risk factors on chronic bisphosphonate therapy. The manufacturer's labeling states that discontinuing bisphosphonates in patients requiring invasive dental procedures may reduce the risk of ONJ. However, other experts suggest that there is no evidence that discontinuing therapy reduces the risk of developing ONJ (Assael, 2009). The benefit/risk must be assessed by the treating physician and/or dentist/surgeon prior to any invasive dental procedure. Patients developing ONJ while on bisphosphonates should receive care by an oral surgeon.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use not recommended with severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Injection: Intravenous bisphosphonates may cause transient decreases in serum calcium and have also been associated with renal toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F181311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: May enhance the hypocalcemic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of antacids containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Magaldrate; Sodium Bicarbonate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral calcium supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Bisphosphonate Derivatives may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral iron supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Bisphosphonate Derivatives. Specifically, polyvalent cation-containing multivitamins may decrease the absorption of orally-administered bisphosphonate derivatives. Management: Avoid administration of polyvalent cation-containing multivitamins within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Bisphosphonate Derivatives may enhance the hypocalcemic effect of Phosphate Supplements.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May diminish the therapeutic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: Bisphosphonate Derivatives may enhance the adverse/toxic effect of SUNItinib. Specifically, the risk of osteonecrosis of the jaw may be increased.  Management: Monitor for development of osteonecrosis of the jaw in patients receiving sunitinib and bisphosphonates.  Avoid invasive dental procedures if possible.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F181332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may increase risk of osteoporosis. Management: Avoid ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: May reduce absorption; mean oral bioavailability is decreased up to 90% when given with food. Management: Take with a full glass (6-8 oz) of plain water, at least 60 minutes prior to any food, beverages, or medications. Mineral water with a high calcium content should be avoided. Wait at least 60 minutes after taking ibandronate before taking anything else.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F181314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F181324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were demonstrated in animal reproduction studies. Bisphosphonates are incorporated into the bone matrix and are gradually released over time. Theoretically, there may be a risk of fetal harm when pregnancy follows the completion of therapy. Based on limited case reports with pamidronate, serum calcium levels in the newborn may be altered if administered during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F181343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F181325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ensure adequate calcium and vitamin D intake; women and men &gt;50 years of age should consume 1200-1500 mg/day of elemental calcium and 800-1000 units/day of vitamin D. Ibandronate tablet should be taken with a full glass (6-8 oz) of plain water, at least 60 minutes prior to any food, beverages, or medications. Mineral water with a high calcium content should be avoided.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Boniva Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mg/3 mL (3 mL): $526.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Boniva Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (3): $486.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ibandronate Sodium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (3): $416.18",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F181315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Osteoporosis: Bone mineral density as measured by central dual-energy x-ray absorptiometry (DXA) of the hip or spine (prior to initiation of therapy and at least every 2 years); annual measurements of height and weight, assessment of chronic back pain; serum calcium and 25(OH)D; may consider measuring biochemical markers of bone turnover",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Serum creatinine prior to each I.V. dose",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F854895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ai Ben (CL);",
"     </li>",
"     <li>",
"      Bandrobon (AR);",
"     </li>",
"     <li>",
"      Bonat (IL);",
"     </li>",
"     <li>",
"      Bondronat (AT, AU, BE, CH, CL, CN, CO, CZ, DE, DK, EC, EE, GR, HK, ID, IE, IT, MX, NL, NO, NZ, PE, PL, RU, SE, TH, TW);",
"     </li>",
"     <li>",
"      Bondronat IV (PH);",
"     </li>",
"     <li>",
"      Bonviva (AT, BE, BG, BR, CH, CN, CO, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, HK, ID, IE, IT, KP, MT, MX, MY, NL, NO, NZ, PE, PH, PL, PT, RU, SE, SG, SK, TH, TR, TW, UY);",
"     </li>",
"     <li>",
"      Etanorden (BG);",
"     </li>",
"     <li>",
"      Idena (CR, DO, EC, GT, HN, NI, SV);",
"     </li>",
"     <li>",
"      Jia Nuo Shun (CL);",
"     </li>",
"     <li>",
"      Tefal (PY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F181306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A bisphosphonate which inhibits bone resorption via actions on osteoclasts or on osteoclast precursors; decreases the rate of bone resorption, leading to an indirect increase in bone mineral density.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F181321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Terminal V",
"     <sub>",
"      d",
"     </sub>",
"     : 90 L; 40% to 50% of circulating ibandronate binds to bone",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 85.7% to 99.5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Not metabolized",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: Minimal; reduced ~90% following standard breakfast",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 150 mg dose: Terminal: 37-157 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Terminal: ~5-25 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Oral: 0.5-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (50% to 60% of absorbed dose, excreted as unchanged drug); feces (unabsorbed drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Dental Association Council on Scientific Affairs, &ldquo;Dental Management of Patients Receiving Oral Bisphosphonate Therapy: Expert Panel Recommendations,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 2006, 137(8):1144-50. Available at file://jada.ada.org/cgi/content/full/137/8/1144",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/8/12423/abstract-text/16873332/pubmed\" id=\"16873332\" target=\"_blank\">",
"        16873332",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Assael LA, &ldquo;Oral Bisphosphonates as a Cause of Bisphosphonate-Related Osteonecrosis of the Jaws: Clinical Findings, Assessment of Risks, and Preventive Strategies,&rdquo;",
"      <i>",
"       J Oral Maxillofac Surg",
"      </i>",
"      , 2009, 67(5 Suppl):35-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/8/12423/abstract-text/19371813/pubmed\" id=\"19371813\" target=\"_blank\">",
"        19371813",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Author Unknown, \"Safety Update: Bone-Building Drugs: Risks Explained,\"",
"      <i>",
"       Consum Rep Health",
"      </i>",
"      , 2006, 18(5):3.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barrett J, Worth E, Bauss F, et al, &ldquo;Ibandronate: A Clinical Pharmacological and Pharmacokinetic Update,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2004, 44(9):951-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/8/12423/abstract-text/15317823/pubmed\" id=\"15317823\" target=\"_blank\">",
"        15317823",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Diel IJ, Body JJ, Lichinitser MR, et al, &ldquo;Improved Quality of Life After Long-Term Treatment With the Bisphosphonate Ibandronate in Patients With Metastatic Bone Disease Due to Breast Cancer,&rdquo;",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 2004, 40(11):1704-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/8/12423/abstract-text/15251160/pubmed\" id=\"15251160\" target=\"_blank\">",
"        15251160",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Edwards BJ, Hellstein JW, Jacobsen PL, et al, \"Updated Recommendations for Managing the Care of Patients Receiving Oral Bisphosphonate Therapy: An Advisory Statement From the American Dental Association Council on Scientific Affairs,\"",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 2008, 139(12):1674-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/8/12423/abstract-text/19047674/pubmed\" id=\"19047674\" target=\"_blank\">",
"        19047674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Filleul O, Crompot E, and Saussez S, \"Bisphosphonate-Induced Osteonecrosis of the Jaw: A Review of 2,400 Patient Cases,\"",
"      <i>",
"       J Cancer Res Clin Oncol",
"      </i>",
"      , 2010, 136(8):1117-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/8/12423/abstract-text/20508948/pubmed\" id=\"20508948\" target=\"_blank\">",
"        20508948",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lo JC, O'Ryan FS, Gordon NP, et al, &ldquo;Prevalence of Osteonecrosis of the Jaw in Patients With Oral Bisphosphonate Exposure,&rdquo;",
"      <i>",
"       J Oral Maxillofac Surg",
"      </i>",
"      , 2010, 68(2):243-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/8/12423/abstract-text/19772941/pubmed\" id=\"19772941\" target=\"_blank\">",
"        19772941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Management of Osteoporosis in Postmenopausal Women: 2010 Position Statement of The North American Menopause Society,&rdquo;",
"      <i>",
"       Menopause",
"      </i>",
"      , 2010, 17(1):25-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/8/12423/abstract-text/20061894/pubmed\" id=\"20061894\" target=\"_blank\">",
"        20061894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marx RE, Sawatari Y, Fortin M, et al, &ldquo;Bisphosphonate-Induced Exposed Bone (Osteonecrosis/Osteopetrosis) of the Jaws: Risk Factors, Recognition, Prevention, and Treatment,&rdquo;",
"      <i>",
"       J Oral Maxillofac Surg",
"      </i>",
"      , 2005, 63(11):1567-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/8/12423/abstract-text/16243172/pubmed\" id=\"16243172\" target=\"_blank\">",
"        16243172",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mavrokokki T, Cheng A, Stein B, et al, &ldquo;Nature and Frequency of Bisphosphonate-Associated Osteonecrosis of the Jaws in Australia,&rdquo;",
"      <i>",
"       J Oral Maxillofac Surg",
"      </i>",
"      , 2007, 65(3):415-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/8/12423/abstract-text/17307586/pubmed\" id=\"17307586\" target=\"_blank\">",
"        17307586",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Osteoporosis Foundation, &ldquo;Clinician&rsquo;s Guide to Prevention and Treatment of Osteoporosis,&rdquo; Washington, DC, 2010. Available at file://www.nof.org/files/nof/public/content/file/344/upload/159.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pecherstorfer M, Steinhauer EU, Rizzoli R, et al, \" Efficacy and Safety of Ibandronate in the Treatment of Hypercalcemia of Malignancy: A Randomized Multicentric Comparison to Pamidronate,\"",
"      <i>",
"       Support Care Cancer",
"      </i>",
"      , 2003, 11(8):539-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/8/12423/abstract-text/12783289/pubmed\" id=\"12783289\" target=\"_blank\">",
"        12783289",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ralston SH, Thi&eacute;baud D, Herrmann Z, et al, \"Dose-Response Study of Ibandronate in the Treatment of Cancer-Associated Hypercalcaemia,\"",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 1997, 75(2):295-300.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/8/12423/abstract-text/9010041/pubmed\" id=\"9010041\" target=\"_blank\">",
"        9010041",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sellmeyer DE, &ldquo;Atypical Fractures as a Potential Complication of Long-term Bisphosphonate Therapy,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2010, 304(13):1480-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/8/12423/abstract-text/20924014/pubmed\" id=\"20924014\" target=\"_blank\">",
"        20924014",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shane E, Burr D, Ebeling PR, et al, &ldquo;Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Report of a Task Force of the American Society for Bone and Mineral Research,&rdquo;",
"      <i>",
"       J Bone Miner Res",
"      </i>",
"      , 2010, 25(11):2267-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/8/12423/abstract-text/20842676/pubmed\" id=\"20842676\" target=\"_blank\">",
"        20842676",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stewart AF, \"Clinical Practice. Hypercalcemia Associated With Cancer,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      ,  2005, 352(4):373-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/8/12423/abstract-text/15673803/pubmed\" id=\"15673803\" target=\"_blank\">",
"        15673803",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tripathy D, Body JJ, and Bergstrom B, &ldquo;Review of Ibandronate in the Treatment of Metastatic Bone Disease: Experience From Phase III Trials,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2004, 26(12):1947-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/8/12423/abstract-text/15823760/pubmed\" id=\"15823760\" target=\"_blank\">",
"        15823760",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Poznak CH, Temin S, Yee GC, et al, &ldquo;American Society of Clinical Oncology Executive Summary of the Clinical Practice Guideline Update on the Role of Bone-Modifying Agents in Metastatic Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(9):1221-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/8/12423/abstract-text/21343561/pubmed\" id=\"21343561\" target=\"_blank\">",
"        21343561",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      von Moos R, &ldquo;Bisphosphonate Treatment Recommendations for Oncologists,&rdquo;",
"      <i>",
"       Oncologist",
"      </i>",
"      , 2005, 10 (Suppl 1):19-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/8/12423/abstract-text/16264109/pubmed\" id=\"16264109\" target=\"_blank\">",
"        16264109",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wysowski DK, &ldquo;Reports of Esophageal Cancer With Oral Bisphosphonate Use,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360(1):89-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/8/12423/abstract-text/19118315/pubmed\" id=\"19118315\" target=\"_blank\">",
"        19118315",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8887 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-F0C764AA00-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_8_12423=[""].join("\n");
var outline_f12_8_12423=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10911787\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181336\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181350\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181338\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181339\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181340\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181341\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181317\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181305\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11441255\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181319\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181318\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181346\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181348\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181322\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181307\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299500\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181311\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181332\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181314\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181324\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181343\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181325\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422242\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181315\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854895\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181306\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181321\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8887\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8887|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/62/5094?source=related_link\">",
"      Ibandronate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_8_12424="Surgery in the treatment of hyperthyroidism: Indications, preoperative preparation, and postoperative follow-up";
var content_f12_8_12424=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgery in the treatment of hyperthyroidism: Indications, preoperative preparation, and postoperative follow-up",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/8/12424/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/8/12424/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/8/12424/contributors\">",
"     Sonia L Sugg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/8/12424/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/8/12424/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/8/12424/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/8/12424/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/8/12424/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of hyperthyroidism consists of both symptomatic relief and decreasing the production of thyroid hormone. The use of surgery as definitive therapy for hyperthyroidism varies with the cause of the disease and the characteristics of the patient.",
"   </p>",
"   <p>",
"    Indications for surgical management of hyperthyroidism and preoperative preparation are reviewed here. Thyroidectomy is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31642?source=see_link\">",
"     \"Initial and reoperative thyroidectomy\"",
"    </a>",
"    .) Other treatment options are also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21143?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of Graves' hyperthyroidism\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12410?source=see_link\">",
"     \"Radioiodine in the treatment of hyperthyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/30/41448?source=see_link\">",
"     \"Treatment of toxic adenoma and toxic multinodular goiter\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18841177\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach outlined below is consistent with Hyperthyroidism Management Guidelines from the American Thyroid Association and the American Association of Clinical Endocrinologists [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12424/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Graves' disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Graves&rsquo; disease can be treated with antithyroid drugs, radioiodine, or surgery. In the only randomized prospective trial comparing these three therapies, each was equally effective in normalizing serum thyroid hormone concentrations within six weeks; after treatment, 95 percent or more of the patients were satisfied with their therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12424/abstract/2\">",
"     2",
"    </a>",
"    ]. Therefore, the choice of therapy should involve active discussion between clinician and patient (",
"    <a class=\"graphic graphic_table graphicRef67833 \" href=\"UTD.htm?33/40/34443\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12424/abstract/3\">",
"     3",
"    </a>",
"    ]. The therapeutic approach to Graves' hyperthyroidism is reviewed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21143?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of Graves' hyperthyroidism\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A patient may prefer surgery over other modalities because of a desire to avoid radioiodine, avoid the potential side effects of antithyroid drugs, and to obtain rapid correction of hyperthyroidism. In addition, the following patients with Graves' hyperthyroidism may be better served by surgery:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with very large goiters (&ge;80 g) may require multiple doses of radioiodine, which can result in asymmetric and limited shrinkage of the goiter.",
"     </li>",
"     <li>",
"      Patients with goiters causing upper airway obstruction or severe dysphagia, which should be removed surgically.",
"     </li>",
"     <li>",
"      For patients who also have a nonfunctional thyroid nodule, which can be a thyroid cancer, surgery can both cure the hyperthyroidism and remove the nodule.",
"     </li>",
"     <li>",
"      For patients with coexisting hyperparathyroidism who are surgical candidates for parathyroidectomy, surgery can cure the hyperthyroidism and hyperparathyroidism.",
"     </li>",
"     <li>",
"      Patients with moderate to severe Graves&rsquo; ophthalmopathy may prefer surgery over radioiodine. Radioiodine may exacerbate Graves' ophthalmopathy, although this may be prevented by coadministering a short course of corticosteroids. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35239?source=see_link\">",
"       \"Treatment of Graves' orbitopathy (ophthalmopathy)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pregnant women who are allergic to antithyroid drugs and are tolerating hyperthyroidism poorly have no alternative to surgery.",
"     </li>",
"     <li>",
"      Patients who have persistent hyperthyroidism despite treatment with antithyroid medication and radioiodine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Toxic adenoma and toxic multinodular goiter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is used more commonly for the treatment of patients with a toxic adenoma or toxic multinodular goiter than it is for Graves' hyperthyroidism. It is indicated for patients with obstructive goiters or very large goiters, those who need rapid and definitive correction of hyperthyroidism, and for patients with coexisting malignancy or primary hyperparathyroidism. Surgery could also be considered in children and adolescents and, as noted above, may be preferable in patients with coexistent nonfunctioning nodules, especially if the goiters are large. The persistence of large areas of cystic degeneration after radioiodine therapy or substernal extension of the goiter are other possible indications for surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12424/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/30/41448?source=see_link&amp;anchor=H460854#H460854\">",
"     \"Treatment of toxic adenoma and toxic multinodular goiter\", section on 'Choice of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18841322\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of substantial comorbidity, including cardiopulmonary disease or other debilitating disease, is a relative contraindication to surgery. Surgery during pregnancy is associated with an increased risk of spontaneous abortion or premature delivery. For pregnant women who require surgery because of an inability to tolerate thionamides, the risks of surgery are minimized by operating during the second trimester. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42760?source=see_link&amp;anchor=H11#H11\">",
"     \"Hyperthyroidism during pregnancy: Treatment\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6617679\">",
"    <span class=\"h1\">",
"     SURGICAL TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extent of surgery for Graves' hyperthyroidism is an area of controversy that parallels the arguments for low versus high doses of radioiodine therapy: more aggressive surgery (total thyroidectomy) with a higher likelihood of inducing hypothyroidism versus less aggressive surgery (subtotal thyroidectomy) with a higher likelihood of recurrent hyperthyroidism. In most cases, total or near-total thyroidectomy is considered the optimal procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12424/abstract/1\">",
"     1",
"    </a>",
"    ]. Surgical complications are lower when performed by surgeons with expertise in thyroid surgery (so-called &ldquo;high volume surgeons&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12424/abstract/1\">",
"     1",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    Subtotal thyroidectomy",
"    <strong>",
"    </strong>",
"    is defined as either bilateral subtotal (leaving posterior rim on each thyroid lobe), or as the",
"    <strong>",
"    </strong>",
"    Hartley-Dunhill procedure (unilateral total lobectomy with contralateral subtotal lobectomy). Up to 60 percent of patients can maintain adequate thyroid function without thyroid hormone supplementation when there is a four to seven gram remnant [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12424/abstract/1\">",
"     1",
"    </a>",
"    ], an important feature for patients without good access to thyroid hormone. However, the remnant predisposes to persistent or recurrent hyperthyroidism. Total thyroidectomy involves removal of all thyroid tissue. Total thyroidectomy has a nearly 0 percent risk of recurrence; however, these patients require life-long thyroxine (T4) replacement therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12424/abstract/5\">",
"     5",
"    </a>",
"    ]. In a randomized trial of subtotal versus total thyroidectomy for Graves&rsquo; disease involving 191 patients followed over five years, recurrent hyperthyroidism occurred in 4.7 percent of patients after subtotal versus none after total thyroidectomy, while transient hypoparathyroidism was seen in 6.8 and 12.6 percent, respectively, and permanent hypoparathyroidism in none and 0.5 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12424/abstract/6\">",
"     6",
"    </a>",
"    ]. If hyperthyroidism persists or recurs after near-total thyroidectomy for Graves&rsquo; disease, patients should be treated with radioiodine because repeat surgery is associated with a high risk of complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12410?source=see_link&amp;anchor=H30632249#H30632249\">",
"     \"Radioiodine in the treatment of hyperthyroidism\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with toxic MNG, near-total or total thyroidectomy should be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12424/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with toxic adenoma without evidence of nodules in the contralateral lobe, ipsilateral lobectomy (or isthmusectomy if the adenoma is in the thyroid isthmus) is adequate. For patients with toxic adenoma and a coexisting nonfunctioning nodule in the contralateral lobe, total thyroidectomy may be warranted. The decision should be based upon results of fine needle aspiration biopsy of the nonfunctioning nodule. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/30/41448?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of toxic adenoma and toxic multinodular goiter\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PREOPERATIVE PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hyperthyroidism are at risk for developing thyroid storm, a rare condition that usually occurs during surgery or in the first 18 hours after the procedure. Thus, patients with hyperthyroidism who are to undergo thyroid surgery should be treated with an antithyroid drug until they are euthyroid. Beta blockers can be used to control hyperthyroid symptoms until euthyroidism is achieved. Patients with Graves' hyperthyroidism may also be given inorganic iodine (eg, saturated solution of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/27/30134?source=see_link\">",
"     potassium iodide",
"    </a>",
"    , 10 drops daily [approximately 400 mg]) for up to 10 days before surgery to decrease the vascularity of the thyroid gland and surgical blood loss [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12424/abstract/7\">",
"     7",
"    </a>",
"    ]. Preoperative iodine is less likely to benefit patients with toxic multinodular goiter or toxic adenoma, whose thyroid glands tend to be less hypervascular than in patients with Graves&rsquo; disease. In addition, iodine may actually exacerbate hyperthyroidism in patients with mild or subclinical hyperthyroidism not treated with antithyroid drugs preoperatively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10852?source=see_link\">",
"     \"Iodine in the treatment of hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Corticosteroids (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    0.5 mg every six hours) have been used in conjunction with beta blockers and iopanoic acid to prepare thyrotoxic patients for emergent surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12424/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10949243\">",
"    <span class=\"h2\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers ameliorate many of the symptoms of hyperthyroidism. They are often started as soon as the diagnosis of hyperthyroidism is made, even before obtaining a 24-hour radioiodine uptake or scan. In the absence of contraindications, we usually give",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    (25 to 50",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    which has the advantages of single daily dosing and beta-1 selectivity, but all drugs of this class effectively reduce symptoms in patients with hyperthyroidism. In addition, for patients who are allergic to or cannot tolerate thionamides, beta blockers administered preoperatively may be as effective as a thionamide for preoperative preparation of the hyperthyroid patient [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12424/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. As an example, in a randomized trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    in 30 patients with newly diagnosed and untreated hyperthyroidism undergoing thyroid surgery, there was no difference in anesthesiologic or cardiovascular complications during surgery or in postoperative complications post-surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12424/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/17/275?source=see_link\">",
"     \"Beta blockers in the treatment of hyperthyroidism\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H8\">",
"     'Patients unable to take a thionamide drug'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Beta blockers may be tapered and discontinued after thyroid function tests have returned to normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Thionamide therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of hyperthyroidism associated with an elevated radioiodine uptake is established, thionamides should be initiated with the aim of controlling hyperthyroidism prior to surgery. Thionamides alone are sufficient to achieve euthyroidism in approximately three to eight weeks. Prior to initiating thionamides, we obtain baseline blood tests, including a complete blood count (white count with differential) and a liver profile (bilirubin and transaminases). We do not use thionamides in patients with a baseline absolute neutrophil count &lt;500 mm3 or elevated liver transaminases (more than fivefold the upper limit of normal) except in selected patients after careful assessment of alternatives and risks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12696?source=see_link\">",
"     \"Thionamides in the treatment of Graves' disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"     Methimazole",
"    </a>",
"    is recommended over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/9/5271?source=see_link\">",
"     propylthiouracil",
"    </a>",
"    (PTU), except during the first trimester of pregnancy, because of its longer duration of action (allowing for single daily dosing) and a lesser degree of toxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41303?source=see_link&amp;anchor=H5#H5\">",
"     \"Pharmacology and toxicity of thionamides\", section on 'Choice of drug'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    is 10 to 15 mg once daily. For patients with larger goiters",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    more severe hyperthyroidism, we typically administer 20 or 30 mg daily. Patients should have their thyroid function assessed at four to six week intervals. The dose can be adjusted if the hyperthyroidism (as assessed clinically and by measurements of serum thyrotropin [TSH], T4, and T3) is not ameliorated within four to six weeks. Methimazole can be discontinued on the day of surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Patients unable to take a thionamide drug",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with toxic nodular goiter or toxic adenoma who are intolerant or unable to take thionamides should be pretreated with beta blockers alone, whereas patients with Graves' hyperthyroidism who are allergic to or are intolerant of thionamides can be treated with the combination of beta blockers and iodine. In the absence of contraindications, a beta-adrenergic antagonist drug should be given in sufficient dose to maintain a pulse rate below 80",
"    <span class=\"nowrap\">",
"     beats/minute",
"    </span>",
"    with exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12424/abstract/11\">",
"     11",
"    </a>",
"    ]. Longer acting drugs of this type, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    , are preferable because an oral dose taken one hour before surgery will maintain adequate blockade until the patient is able to take oral medications postoperatively. Supplemental intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    can be administered as needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/17/275?source=see_link\">",
"     \"Beta blockers in the treatment of hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10949250\">",
"    <span class=\"h2\">",
"     Iodine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inorganic iodine rapidly (7 to 10 days) decreases thyroid secretion, in addition to decreasing thyroid vascularity. Thus, in patients with Graves&rsquo; disease, we administer inorganic iodine (eg, saturated solution of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/27/30134?source=see_link\">",
"     potassium iodide",
"    </a>",
"    , 10 drops daily [approximately 400 mg]) for up to 10 days before surgery to decrease the vascularity of the thyroid gland and surgical blood loss [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12424/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10852?source=see_link\">",
"     \"Iodine in the treatment of hyperthyroidism\"",
"    </a>",
"    .) Alternatively, the patient with Graves&rsquo; disease can be given sodium ipodate or iopanoic acid, iodinated radiographic contrast agents, that not only contains iodine but also inhibit the extrathyroidal conversion of T4 to triiodothyronine (T3) and therefore rapidly lowers serum T3 concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12424/abstract/8\">",
"     8",
"    </a>",
"    ]. Neither is available in the United States. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37779?source=see_link\">",
"     \"Iodinated radiocontrast agents in the treatment of hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18841213\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of thyroid surgery include wound infection, keloid formation at the site of the incision, transient and permanent hypoparathyroidism, and recurrent or superior laryngeal nerve palsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31642?source=see_link&amp;anchor=H27#H27\">",
"     \"Initial and reoperative thyroidectomy\", section on 'Postoperative complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Permanent problems should occur in less than 1 to 2 percent of patients, although slightly higher complication rates have been described. As an example, in a series of 380 patients with hyperthyroidism who underwent surgery (98 percent subtotal thyroidectomy), complications included [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12424/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Transient vocal cord paralysis in 3 percent",
"     </li>",
"     <li>",
"      Prolonged postoperative hypocalcemia in 3 percent",
"     </li>",
"     <li>",
"      Permanent hypoparathyroidism in 1 percent",
"     </li>",
"     <li>",
"      Recurrent hyperthyroidism in 2 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     FOLLOW-UP AND MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers, if administered, should be tapered and discontinued after thyroidectomy. Antithyroid drugs can be discontinued at the time of thyroidectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10949435\">",
"    <span class=\"h2\">",
"     Hypocalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the first 24 hours after total thyroidectomy for hyperthyroidism, transient biochemical hypocalcemia is common, occurring in 60 to 90 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12424/abstract/5,13-15\">",
"     5,13-15",
"    </a>",
"    ]. Permanent hypoparathyroidism is uncommon, occurring in approximately 1 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12424/abstract/5\">",
"     5",
"    </a>",
"    ]. Monitoring for hypocalcemia after near-total or total thyroidectomy is necessary. Serum calcium and albumin should be measured on the evening of surgery and the next morning. Oral calcium and calcitriol supplementation should be administered based upon the results of the serum calcium corrected for albumin (",
"    <a class=\"graphic graphic_table graphicRef59019 \" href=\"UTD.htm?28/57/29596\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Alternatively, and especially in patients whose risk of postoperative hypocalcemia is high, the routine supplementation of calcium and calcitriol may decrease the development of hypocalcemia symptoms and allow for earlier discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12424/abstract/16\">",
"     16",
"    </a>",
"    ]. In many centers, a serum parathyroid hormone (PTH) level is checked in the immediate postoperative period and is used to predict risk of hypocalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12424/abstract/17\">",
"     17",
"    </a>",
"    ]. In a meta-analysis of nine studies evaluating pre- and post-thyroidectomy serum PTH levels, the magnitude of the reduction in serum PTH was predictive of the development of postoperative hypocalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12424/abstract/18\">",
"     18",
"    </a>",
"    ]. Patients with a &gt;65 percent decline in PTH were at highest risk for postoperative hypocalcemia. In subsequent studies, a postoperative (one to six hours) serum PTH level &lt;10 to 15",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    was predictive of postoperative hypocalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12424/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Thus, when the risk of post-thyroidectomy hypocalcemia is high (eg, if the surgery was difficult and the surgeon feels the parathyroids may have been compromised, or if the intraoperative or postoperative parathyroid hormone levels are less than 10 to 15",
"    <span class=\"nowrap\">",
"     pg/mL),",
"    </span>",
"    the routine supplementation of calcium and calcitriol is preferred. A typical prophylactic dose of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    is approximately 2 to 3 g of elemental calcium given in two to four divided doses daily. This can be tapered over two to six weeks depending upon hypocalcemic symptoms and serum calcium determinations. Calcitriol is initially administered at a dose of 0.5 mcg daily for one to two weeks and increased or decreased thereafter depending upon the calcium and intact parathyroid hormone levels [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12424/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients can be discharged if they are asymptomatic and have stable serum calcium levels (at least 7.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.95",
"    <span class=\"nowrap\">",
"     mmol/L]).",
"    </span>",
"   </p>",
"   <p>",
"    The management of post-thyroidectomy hypoparathyroidism is reviewed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41064?source=see_link&amp;anchor=H16#H16\">",
"     \"Surgical treatment of differentiated thyroid cancer\", section on 'Hypoparathyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10949470\">",
"    <span class=\"h2\">",
"     Hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of postoperative hypothyroidism is dependent upon the size of the surgical remnant. For patients with Graves&rsquo; disease or toxic MNG who had near-total or total thyroidectomy, thyroid hormone replacement (thyroxine, T4) should be initiated prior to discharge in a euthyroid patient at a dose of approximately 1.6",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    body weight daily. If the patient was still hyperthyroid at the time of surgery, thyroid hormone replacement should be delayed until levels fall into the normal range; the interval can be estimated based on the week-long half-life of T4. Elderly patients and those with coronary disease or multiple coronary risk factors should be treated with less than full replacement dose (ie, 50 to 75 mcg daily). Serum TSH should be measured in six to eight weeks and the dose increased by 12 to 25",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    if the TSH remains above the normal reference range. Serum TSH should be measured six to eight weeks after each dose adjustment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of hypothyroidism\", section on 'Dose and monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with Graves&rsquo; disease who have subtotal thyroidectomy and are not hypothyroid soon after surgery need to be monitored for possible hypothyroidism (or recurrent hyperthyroidism) for the rest of their lives.",
"    <br/>",
"   </p>",
"   <p>",
"    Hypothyroidism is less common after lobectomy or isthmusectomy for toxic adenoma. Serum TSH and free T4 levels should be measured four to six weeks after surgery. Thyroid hormone should be initiated only if the TSH rises and remains above the normal reference range.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/9/22674?source=see_link\">",
"       \"Patient information: Hyperthyroidism (overactive thyroid) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=see_link\">",
"       \"Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/15/23794?source=see_link\">",
"       \"Patient information: Antithyroid drugs (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18841476\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A patient may prefer surgery over other modalities to treat hyperthyroidism because of a desire to avoid radioiodine, avoid the potential side effects of antithyroid drugs, and obtain rapid correction of hyperthyroidism. Patients with symptoms or signs of",
"      <span class=\"nowrap\">",
"       compression/obstruction,",
"      </span>",
"      a need for rapid return to euthyroidism, or coexisting thyroid cancer require surgery. (See",
"      <a class=\"local\" href=\"#H18841177\">",
"       'Indications'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For patients with Graves&rsquo; disease, we suggest radioiodine therapy as our first choice for definitive therapy of the hyperthyroidism, given its lower cost and lower complication rate than surgery (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Primary antithyroid drug therapy is an alternative option for patients with mild Graves&rsquo; disease and small goiters. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21143?source=see_link&amp;anchor=H2#H2\">",
"       \"Treatment of Graves' hyperthyroidism\", section on 'Treatment'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      For patients with toxic adenoma or multinodular goiter, we suggest treatment with either surgery or radioiodine rather than prolonged thionamide (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In addition, for patients with hyperthyroidism due to a very large goiter (&gt;80 g), we suggest surgery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/30/41448?source=see_link\">",
"       \"Treatment of toxic adenoma and toxic multinodular goiter\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presence of substantial comorbidity, including cardiopulmonary disease or other debilitating disease, is a relative contraindication to surgery. Surgery during pregnancy is associated with an increased risk of spontaneous abortion or premature delivery. For pregnant women who require surgery because of an inability to tolerate thionamides, the risks of surgery are minimized by operating during the second trimester. (See",
"      <a class=\"local\" href=\"#H18841322\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Assuming there are no contraindications to its use,",
"      <strong>",
"      </strong>",
"      we recommend",
"      <strong>",
"      </strong>",
"      using a beta blocker for patients with moderate-to-severe hyperadrenergic symptoms until euthyroidism is achieved by thionamides or surgery (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We typically start with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      25 to 50 mg daily and increase the dose as needed (up to 200 mg daily) to reduce pulse to less than 90 beats per minute if blood pressure allows. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/17/275?source=see_link\">",
"       \"Beta blockers in the treatment of hyperthyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with hyperthyroidism are at risk for developing thyroid storm, a rare condition that usually occurs during surgery or in the first 18 hours after the procedure. Thus, for patients with hyperthyroidism associated with an elevated radioiodine uptake who are to undergo thyroidectomy, we suggest treating with a thionamide until they are euthyroid (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"       Methimazole",
"      </a>",
"      is preferred over",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/9/5271?source=see_link\">",
"       propylthiouracil",
"      </a>",
"      (PTU), except during the first trimester of pregnancy, because of its longer duration of action (allowing for single daily dosing) and a lesser degree of toxicity. The initial dose of methimazole is 10 to 15 mg once daily. For patients with larger goiters",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      more severe hyperthyroidism, we typically administer 20 or 30 mg daily. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Preoperative preparation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12696?source=see_link\">",
"       \"Thionamides in the treatment of Graves' disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41303?source=see_link&amp;anchor=H5#H5\">",
"       \"Pharmacology and toxicity of thionamides\", section on 'Choice of drug'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with Graves' hyperthyroidism, we suggest adding potassium iodine solution to decrease the vascularity of the thyroid gland and surgical blood loss (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We typically use saturated solution of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/27/30134?source=see_link\">",
"       potassium iodide",
"      </a>",
"      , 10 drops daily (approximately 400 mg) for up to 10 days before surgery. Preoperative iodine is less likely to benefit patients with toxic multinodular goiter or toxic adenoma, whose thyroid glands tend to be less hypervascular than in patients with Graves&rsquo; disease. In addition, iodine may actually exacerbate hyperthyroidism in patients with mild or subclinical hyperthyroidism not treated with antithyroid drugs preoperatively. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Preoperative preparation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10852?source=see_link&amp;anchor=H5852546#H5852546\">",
"       \"Iodine in the treatment of hyperthyroidism\", section on 'Indications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with toxic nodular goiter or toxic adenoma who are intolerant or unable to take thionamides should be pretreated with beta blockers alone, whereas patients with Graves' hyperthyroidism who are allergic to or are intolerant of thionamides can be treated with the combination of beta blockers and iodine. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Patients unable to take a thionamide drug'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of the high risk of hypocalcemia after thyroidectomy, serum calcium concentration should be measured the evening and first morning after thyroidectomy. Treatment of postoperative hypocalcemia should be tailored to the severity and expected duration of parathyroid deficiency (",
"      <a class=\"graphic graphic_table graphicRef59019 \" href=\"UTD.htm?28/57/29596\">",
"       table 2",
"      </a>",
"      ). When the risk of post-thyroidectomy hypocalcemia is high (eg, if the surgery was difficult and the surgeon feels the parathyroids may have been compromised, or if the intraoperative or postoperative parathyroid hormone levels are less than 10 to 15",
"      <span class=\"nowrap\">",
"       pg/mL),",
"      </span>",
"      the patient is routinely supplemented with calcium and calcitriol. A typical prophylactic dose of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"       calcium carbonate",
"      </a>",
"      is approximately 2 to 3 g of elemental calcium by mouth given in two to four divided doses daily. This can be tapered over two to six weeks depending upon hypocalcemic symptoms and serum calcium determinations. Calcitriol is administered at a dose of 0.5 mcg daily for one to two weeks and increased or decreased thereafter depending upon the calcium and intact parathyroid hormone levels. (See",
"      <a class=\"local\" href=\"#H10949435\">",
"       'Hypocalcemia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41064?source=see_link&amp;anchor=H16#H16\">",
"       \"Surgical treatment of differentiated thyroid cancer\", section on 'Hypoparathyroidism'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with Graves&rsquo; disease or toxic MNG who had near-total or total thyroidectomy, thyroid hormone replacement (thyroxine, T4) should be initiated prior to discharge in euthyroid patients at a dose of approximately 1.6",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      body weight daily. If the patient was still hyperthyroid at the time of surgery, thyroid hormone replacement should be delayed until levels fall into the normal range; the interval can be estimated based on the week-long half-life of T4. Elderly patients and those with coronary disease or multiple coronary risk factors should be treated with less than full replacement dose (ie, 50 to 75 mcg daily). Serum TSH should be measured in six to eight weeks and the dose increased by 12 to 25",
"      <span class=\"nowrap\">",
"       mcg/day",
"      </span>",
"      if the TSH remains above the normal reference range. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Follow-up and monitoring'",
"      </a>",
"      above.) Patients with Graves&rsquo; disease who have subtotal thyroidectomy and are not hypothyroid soon after surgery need to be monitored for possible hypothyroidism (or recurrent hyperthyroidism) for the rest of their lives.",
"      <br/>",
"      <br/>",
"      Hypothyroidism is less common after lobectomy or isthmusectomy for toxic adenoma. Serum TSH and free T4 levels should be measured four to six weeks after surgery. Thyroid hormone should be initiated only if the TSH rises and remains above the normal reference range. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Follow-up and monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12424/abstract/1\">",
"      Bahn Chair RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011; 21:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12424/abstract/2\">",
"      T&ouml;rring O, Tallstedt L, Wallin G, et al. Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine--a prospective, randomized study. Thyroid Study Group. J Clin Endocrinol Metab 1996; 81:2986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12424/abstract/3\">",
"      Ross DS. Radioiodine therapy for hyperthyroidism. N Engl J Med 2011; 364:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12424/abstract/4\">",
"      Katlic MR, Grillo HC, Wang CA. Substernal goiter. Analysis of 80 patients from Massachusetts General Hospital. Am J Surg 1985; 149:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12424/abstract/5\">",
"      Palit TK, Miller CC 3rd, Miltenburg DM. The efficacy of thyroidectomy for Graves' disease: A meta-analysis. J Surg Res 2000; 90:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12424/abstract/6\">",
"      Barczyski M, Konturek A, Hubalewska-Dydejczyk A, et al. Randomized clinical trial of bilateral subtotal thyroidectomy versus total thyroidectomy for Graves' disease with a 5-year follow-up. Br J Surg 2012; 99:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12424/abstract/7\">",
"      Erbil Y, Ozluk Y, Giri M, et al. Effect of lugol solution on thyroid gland blood flow and microvessel density in the patients with Graves' disease. J Clin Endocrinol Metab 2007; 92:2182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12424/abstract/8\">",
"      Baeza A, Aguayo J, Barria M, Pineda G. Rapid preoperative preparation in hyperthyroidism. Clin Endocrinol (Oxf) 1991; 35:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12424/abstract/9\">",
"      Adlerberth A, Stenstr&ouml;m G, Hasselgren PO. The selective beta 1-blocking agent metoprolol compared with antithyroid drug and thyroxine as preoperative treatment of patients with hyperthyroidism. Results from a prospective, randomized study. Ann Surg 1987; 205:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12424/abstract/10\">",
"      Vickers P, Garg KM, Arya R, et al. The role of selective beta 1-blocker in the preoperative preparation of thyrotoxicosis: a comparative study with propranolol. Int Surg 1990; 75:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12424/abstract/11\">",
"      Feek CM, Sawers JS, Irvine WJ, et al. Combination of potassium iodide and propranolol in preparation of patients with Graves' disease for thyroid surgery. N Engl J Med 1980; 302:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12424/abstract/12\">",
"      Werga-Kjellman P, Zedenius J, Tallstedt L, et al. Surgical treatment of hyperthyroidism: a ten-year experience. Thyroid 2001; 11:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12424/abstract/13\">",
"      Hughes OR, Scott-Coombes DM. Hypocalcaemia following thyroidectomy for treatment of Graves' disease: implications for patient management and cost-effectiveness. J Laryngol Otol 2011; 125:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12424/abstract/14\">",
"      Welch KC, McHenry CR. Total thyroidectomy: is morbidity higher for Graves' disease than nontoxic goiter? J Surg Res 2011; 170:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12424/abstract/15\">",
"      Pesce CE, Shiue Z, Tsai HL, et al. Postoperative hypocalcemia after thyroidectomy for Graves' disease. Thyroid 2010; 20:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12424/abstract/16\">",
"      Bellantone R, Lombardi CP, Raffaelli M, et al. Is routine supplementation therapy (calcium and vitamin D) useful after total thyroidectomy? Surgery 2002; 132:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12424/abstract/17\">",
"      Landry CS, Grubbs EG, Hernandez M, et al. Predictable criteria for selective, rather than routine, calcium supplementation following thyroidectomy. Arch Surg 2012; 147:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12424/abstract/18\">",
"      Noordzij JP, Lee SL, Bernet VJ, et al. Early prediction of hypocalcemia after thyroidectomy using parathyroid hormone: an analysis of pooled individual patient data from nine observational studies. J Am Coll Surg 2007; 205:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12424/abstract/19\">",
"      Erbil Y, Ozbey NC, Sari S, et al. Determinants of postoperative hypocalcemia in vitamin D-deficient Graves' patients after total thyroidectomy. Am J Surg 2011; 201:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12424/abstract/20\">",
"      Cote V, Sands N, Hier MP, et al. Cost savings associated with post-thyroidectomy parathyroid hormone levels. Otolaryngol Head Neck Surg 2008; 138:204.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7880 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-9EF4B3CCD6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_8_12424=[""].join("\n");
var outline_f12_8_12424=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18841476\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18841177\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Toxic adenoma and toxic multinodular goiter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18841322\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6617679\">",
"      SURGICAL TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PREOPERATIVE PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10949243\">",
"      Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Thionamide therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Patients unable to take a thionamide drug",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10949250\">",
"      Iodine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18841213\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      FOLLOW-UP AND MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10949435\">",
"      Hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10949470\">",
"      Hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18841476\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7880\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7880|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/40/34443\" title=\"table 1\">",
"      Treatment Graves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/57/29596\" title=\"table 2\">",
"      Management of hypocalcemia after thyroid surgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/17/275?source=related_link\">",
"      Beta blockers in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42760?source=related_link\">",
"      Hyperthyroidism during pregnancy: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31642?source=related_link\">",
"      Initial and reoperative thyroidectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37779?source=related_link\">",
"      Iodinated radiocontrast agents in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10852?source=related_link\">",
"      Iodine in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/15/23794?source=related_link\">",
"      Patient information: Antithyroid drugs (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/9/22674?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41303?source=related_link\">",
"      Pharmacology and toxicity of thionamides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12410?source=related_link\">",
"      Radioiodine in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41064?source=related_link\">",
"      Surgical treatment of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12696?source=related_link\">",
"      Thionamides in the treatment of Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21143?source=related_link\">",
"      Treatment of Graves' hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35239?source=related_link\">",
"      Treatment of Graves' orbitopathy (ophthalmopathy)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=related_link\">",
"      Treatment of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/30/41448?source=related_link\">",
"      Treatment of toxic adenoma and toxic multinodular goiter",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_8_12425="Lung transplantation: Deceased donor evaluation and management";
var content_f12_8_12425=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lung transplantation: Deceased donor evaluation and management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/8/12425/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/8/12425/contributors\">",
"     Pamela J McShane, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/8/12425/contributors\">",
"     Edward R Garrity, MD, MBA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/8/12425/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/8/12425/contributors\">",
"     Elbert P Trulock, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/8/12425/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/8/12425/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/8/12425/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal selection and care of donor lungs for transplant are needed to increase the number of available lungs. Deceased donor evaluation, selection, and management after brain and cardiac death will be reviewed here from the lung transplant perspective. Living donor lobar transplants are rare in comparison to deceased donor lung transplants.",
"   </p>",
"   <p>",
"    The indications for lung transplantation, selection of lung transplant recipients, and donor lung preservation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3480?source=see_link\">",
"     \"Lung transplantation: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26953?source=see_link\">",
"     \"Lung transplantation: General guidelines for recipient selection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5640?source=see_link\">",
"     \"Lung transplantation: Donor lung preservation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DONATION AFTER BRAIN DEATH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Donor evaluation begins with the notification of the local Organ Procurement Organization (OPO) of a potential donor. A member of the OPO, or a provider trained in the consent of families for organ donation, should approach the family as soon as reasonable after the determination of brain death [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30761?source=see_link\">",
"     \"Diagnosis of brain death\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When the patient has signed an irrevocable consent for transplant (offered through some state registries), the OPO staff will support the family through the organ retrieval and grieving process. If consent has not already been provided by the patient, the OPO staff will explain the procurement process to the family, including the dignity of the process and implications for funeral arrangements, and obtain their consent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/2\">",
"     2",
"    </a>",
"    ]. The OPO staff will also coordinate evaluation of the donor for suitability for transplant and will communicate with the United Network for Organ Sharing (UNOS) to match the donor with an appropriate recipient from the waiting list. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3480?source=see_link\">",
"     \"Lung transplantation: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DONATION AFTER CARDIAC DEATH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Donation after cardiac death (also called nonheartbeating donor) has become an accepted method of increasing the donor pool in some transplant centers and organ procurement organizations (OPO), although the exact definition of cardiac death and the timing of organ harvest remain controversial. Nonheartbeating donors can be classified according to the Maastricht system, which was developed in 1995 and revised in 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      I Dead on arrival to hospital",
"     </li>",
"     <li>",
"      II Unsuccessful resuscitation",
"     </li>",
"     <li>",
"      III Awaiting cardiac arrest (Inpatient withdrawal of support)",
"     </li>",
"     <li>",
"      IV Cardiac arrest after brain-stem death",
"     </li>",
"     <li>",
"      V Cardiac arrest in a hospital inpatient",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some experts recommend that the phrase &ldquo;donation after circulatory determination of death&rdquo; (DCDD) replace &ldquo;donation after cardiac death&rdquo;. These experts emphasize that organ donation occurs after cessation of circulatory and respiratory, not cardiac, function [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/5\">",
"     5",
"    </a>",
"    ]. There is no official consensus to change this terminology, however.",
"   </p>",
"   <p>",
"    Since the first successful transplantation of lungs from a nonheartbeating donor in 2001, ethical and legal frameworks have been put in place to investigate and utilize increasing numbers of allografts from non-heart-beating donors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/6\">",
"     6",
"    </a>",
"    ]. Donation after cardiac death accounts for only a small percentage of deceased organ donors. In 2007, 16 lungs from nonheartbeating donors were transplanted, less than the 22 lungs transplanted in 2006 when this number had been steadily increasing (2008",
"    <span class=\"nowrap\">",
"     OPTN/SRTR",
"    </span>",
"    Annual Report available at www.ustransplant.org [Accessed on Aug 2, 2010]).",
"   </p>",
"   <p>",
"    Situations in which donation after cardiac death may be considered include irreversible brain injury, end stage musculoskeletal disease, and high spinal cord injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. These criteria may be used when the donor does not meet criteria for brain death. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Donation after brain death'",
"    </a>",
"    above.) Other situations include sudden death without significant thoracic or abdominal trauma, known time of cardiac arrest and cardiopulmonary resuscitation maneuvers started within 15 minutes of cardiac arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The details of protocols and management recommendations for donation after cardiac death have been the subject of a consensus conference [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      By definition, death precedes organ procurement and requires cardiopulmonary criteria to prove absence of circulation [",
"      <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Determination of death must meet criteria for irreversible cessation of function; procurement of organs should not cause death of the donor [",
"      <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The main criterion for cardiac death is absence of circulation, which may be assessed via an indwelling arterial line or Doppler study.",
"     </li>",
"     <li>",
"      Electrocardiographic (ECG) silence is not a necessary criterion in the absence of circulation, but may be used as a confirmatory test; ECG silence alone is adequate evidence that circulation has ceased.",
"     </li>",
"     <li>",
"      The conference concluded that after cessation of circulation \"at least 2 minutes of observation is required, and more than 5 minutes is not recommended\" for declaration of death.",
"     </li>",
"     <li>",
"      In the setting of withdrawal of life sustaining treatment, the time limit to cardiac death after treatment withdrawal may be up to two hours and still enable organ recovery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The local OPO staff should become involved immediately after the decision is made to withdraw life sustaining treatment. The OPO staff will coordinate communication with UNOS, the transplant team, and the family and will coordinate evaluation of the donor's suitability for transplant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3480?source=see_link\">",
"     \"Lung transplantation: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12653407\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comparison of lung transplantation graft survival after donation after cardiac death compared with donation after brain death has revealed equivalent results. As an example, a 16-year, single center, study that included 18 lung transplantations after cardiac death showed that patient survival rates at 1, 3, and 5 years did not differ between donation after cardiac death and donation after brain-death. In addition, the incidence of primary graft dysfunction and freedom from bronchiolitis obliterans were not significantly different between the two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/11\">",
"     11",
"    </a>",
"    ]. Strategies to maintain the integrity of the allograft and reduce ischemic times from the moment of cardiac death to transplantation are key to the success of donation after cardiac death. A discussion of potential interventions to preserve lung function is presented below. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Donor management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DONOR SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;No controlled data exist to determine what constitutes ideal donor candidacy. Consensus and experience have identified some ideal and other less than ideal, or \"expanded\", donor characteristics that are reviewed here.",
"   </p>",
"   <p>",
"    Since the lung donor usually will be donating other organs, coordination between transplant teams is critical, so that all teams are ready to recover organs at nearly the same time. Further information regarding donor organ preservation is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5640?source=see_link\">",
"     \"Lung transplantation: Donor lung preservation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Size matching",
"    </span>",
"    &nbsp;&mdash;&nbsp;Matching of the size of a donor lung with a recipient is usually based on donor and recipient height, although some centers also use estimates of lung volume made from chest radiographs [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. While the optimal degree of fit is unknown and the correlation between donor and recipient size need not be perfect, a close size match is preferred [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/14\">",
"     14",
"    </a>",
"    ]. The underlying disease of the recipient may affect this, since the larger thoracic cavity of an emphysematous patient may be more amenable to a larger donor lung, and a smaller lung may fit well in the thoracic cavity of a patient with pulmonary fibrosis.",
"   </p>",
"   <p>",
"    The effect of lung size mismatch was examined in 159 adult bilateral lung transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/12\">",
"     12",
"    </a>",
"    ]. Assessment of size matching was based on predicted values for gender and height. At one and six months, recipients with &ldquo;oversized&rdquo; lungs had higher expiratory airflow capacity based on higher ratios of forced expiratory volume in one second",
"    <span class=\"nowrap\">",
"     (FEV",
"     <sub>",
"      1",
"     </sub>",
"     )/forced",
"    </span>",
"    vital capacity (FVC), than those with &ldquo;undersized&rdquo; lungs. The probability of developing bronchiolitis obliterans syndrome, defined as a decrease of more than 20 percent from the highest post-transplant FEV",
"    <sub>",
"     1",
"    </sub>",
"    , was lower among those with oversized lungs. Further study is needed to determine the effects of lung size mismatch. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=see_link\">",
"     \"Chronic lung transplant rejection: Bronchiolitis obliterans\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some cases, donors are ideal matches for recipients in many ways, except for size of the lung. In these cases, an alternative may be to perform a split lung bilateral lobar lung transplant or to down size a large donor lung by lobectomy or wedge resection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31192?source=see_link\">",
"     \"Lung transplantation: Disease-based choice of procedure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Ideal donor criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Criteria based on expert opinion and transplant experience have been established for 'ideal' donor candidates (",
"    <a class=\"graphic graphic_table graphicRef74075 \" href=\"UTD.htm?22/34/23083\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/16\">",
"     16",
"    </a>",
"    ]. These criteria include: age less than 55 years, clear chest radiograph,",
"    <span class=\"nowrap\">",
"     PaO",
"     <sub>",
"      2",
"     </sub>",
"     /FiO",
"     <sub>",
"      2",
"     </sub>",
"    </span>",
"    &gt;300 mmHg at PEEP 5, less than 20 pack year smoking history, absence of chest trauma, no evidence of aspiration or sepsis, no prior cardiopulmonary surgery, and absence of purulent secretions on bronchoscopic visualization prior to harvesting the lungs.",
"   </p>",
"   <p>",
"    Donors should be excluded if they are infected with HIV, human T-cell leukemia-lymphoma virus, or have active systemic viral infection (eg, measles, rabies, adenovirus, enterovirus, West Nile and parvovirus), prion-related disease, or herpetic meningoencephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Certain other infections may also make organ donation less desirable. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Donor infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Any donor satisfying these ideal inclusion and exclusion criteria should be considered for lung donation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Expanded donor criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definition of expanded donor criteria is not as well developed for lung transplantation as for kidney transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/19\">",
"     19",
"    </a>",
"    ]. However, in order to reduce long wait list time for lung transplant, efforts are being made to expand the donor pool by using donors who do not meet ideal criteria (",
"    <a class=\"graphic graphic_table graphicRef74075 \" href=\"UTD.htm?22/34/23083\">",
"     table 1",
"    </a>",
"    ). When an extended criteria donor is being considered, effective communication between the Organ Procurement Organization (OPO) coordinator and the transplant teams is essential. Each transplant team must know the original and current conditions of the donor. While outcomes for less-than-ideal criteria are acceptable, it is still the choice of the surgeon to accept a less-than-ideal donor lung. Some retrospective studies have examined outcomes for these expanded donor criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/16,20-25\">",
"     16,20-25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Advanced donor age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fifty-five years has been regarded as the upper age limit for an 'ideal' candidate, based on the belief that accrual of comorbid conditions occurs as age increases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/26\">",
"     26",
"    </a>",
"    ]. A few studies have examined using lungs from older donors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/16,21,23,24\">",
"     16,21,23,24",
"    </a>",
"    ]. Results are mixed, with some indication of increased risk to the recipient, although other risk factors (such as ischemic time) may explain the difference. Other studies have not shown a significant difference in outcomes when donors as old as 65 have been used [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     ABO compatibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;ABO-identical matches are preferred and may lead to a survival advantage over ABO-compatible matches. However, there is reported success using ABO-compatible rather than ABO-identical matches [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A successful outcome was reported in one patient with an ABO incompatible lung transplant who was given additional immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/29\">",
"     29",
"    </a>",
"    ]. However, lung transplant in the setting of ABO incompatibility is not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Abnormal chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with abnormalities on the chest radiograph should not be automatically rejected from donation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/20\">",
"     20",
"    </a>",
"    ]. If the lesion is unilateral, the unaffected lung may be used for transplant. Opacities on the chest radiograph should prompt early bronchoscopy to address the character and volume of secretions. Ventilator recruitment maneuvers may clear areas of atelectasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13113?source=see_link&amp;anchor=H18#H18\">",
"     \"Strategies to reduce postoperative pulmonary complications\", section on 'Lung expansion'",
"    </a>",
"    .) The combination of opacities on chest radiograph and purulent sputum on bronchoscopy was associated with a lower early survival in the transplant recipients in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103242957\">",
"    <span class=\"h3\">",
"     Cytomegalovirus antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of antibodies to cytomegalovirus was associated with increased mortality in a retrospective study of 10,333 lung transplants, although this has not traditionally been considered an exclusionary donor criterion [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/25\">",
"     25",
"    </a>",
"    ]. Further study of this potential risk factor for decreased lung transplant recipient survival is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Low PaO2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several reports have examined using donors who do not start with an ideal PaO",
"    <sub>",
"     2",
"    </sub>",
"    (PaO",
"    <sub>",
"     2",
"    </sub>",
"    &gt;300 mmHg on FiO",
"    <sub>",
"     2",
"    </sub>",
"    = 1.0, PEEP = 5 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/20,21,24,30\">",
"     20,21,24,30",
"    </a>",
"    ]. While there are isolated reports of graft failure in this setting, others have reported no increased risk to the recipient [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/20,21,24,25,30\">",
"     20,21,24,25,30",
"    </a>",
"    ]. If the PaO",
"    <sub>",
"     2",
"    </sub>",
"    starts below goal, aggressive recruitment strategies should be used to increase the number of functional lung units. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11434?source=see_link\">",
"     \"Overview of the management of postoperative pulmonary complications\"",
"    </a>",
"    .) The same criteria should be applied at the end of the recruitment maneuver, and there must be evidence for a sustained effect before the lungs are offered for donation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103242891\">",
"    <span class=\"h3\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a retrospective series of 10,333 lung transplantations performed in the United States, a donor history of diabetes was associated with an increase in mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/25\">",
"     25",
"    </a>",
"    ]. Diabetes has not traditionally been a criterion for donor lung exclusion, so further study of this potential risk factor for decreased lung transplant recipient survival is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two main concerns for transplantation of lungs from a donor with a substantial smoking history are the potential for adverse effects on post transplant lung",
"    <span class=\"nowrap\">",
"     function/survival",
"    </span>",
"    and the transmission of cancer that is not evident on chest x-ray [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/25,26,31-33\">",
"     25,26,31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Generally, moderate to severe COPD or emphysema is apparent by history, oxygenation, ventilator mechanics, chest radiograph, or some combination of these. However, clinically inapparent effects of smoking may affect post transplant survival. In a retrospective study of 510 transplant recipients who received lungs from donors with a smoking history compared with 712 recipients from nonsmoking donors, the three-year mortality was greater in those who received lungs from donors with a positive smoking history (adjusted HR 1.36, 95% CI, 1.11&ndash;1.67) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/33\">",
"     33",
"    </a>",
"    ]. The groups did not differ in baseline age or arterial blood oxygen tension. In addition, recipients of lungs from donors who had smoked had longer stays in the hospital and intensive-care units than did those who received lungs from nonsmokers. On the other hand, receiving transplanted lungs from a donor with a smoking history is associated with a lower unadjusted hazard of death than remaining on the waiting list without a transplant (0.79, 95% CI 0.70&ndash;0.91).",
"   </p>",
"   <p>",
"    While there are case reports of bronchogenic carcinoma of donor origin in the transplanted lung, these are rare, and the donors had substantial smoking histories [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/26,31\">",
"     26,31",
"    </a>",
"    ]. If the donor lungs are otherwise acceptable, increasing the donor pack-year limit will likely not increase the chances of a poor recipient outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/25,32\">",
"     25,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;With a few exceptions a history of malignancy is an absolute contraindication to organ donation. Low-grade skin cancer (not melanoma) and carcinoma-in-situ (for example, of the cervix) have an exceedingly low potential for metastasis and thus should not be exclusionary factors. Donors with a remote history of treated malignancy should also be considered; the optimal time since diagnosis or treatment has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Primary central nervous system (CNS) tumors are unlikely to have spread past the blood-brain barrier. However, high-grade tumors, particularly glioblastomas or medulloblastomas, are at increased risk of metastasis and may represent contraindications to transplant. Craniotomy, ventricular shunts, and radiation to the tumor also increase the chance of tumor spread [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Donor infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transmission of infection from the donor to the lung transplant recipient is a significant risk for the recipient (",
"    <a class=\"graphic graphic_table graphicRef76293 \" href=\"UTD.htm?40/34/41515\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/17,35\">",
"     17,35",
"    </a>",
"    ]. Certain donor infections do not limit transplant, provided the donor and recipient receive adequate treatment. In general, donor infection with gram positive organisms appears to affect outcomes less than gram negative infections. Invasive fungal disease is a contraindication.",
"   </p>",
"   <p>",
"    Bacterial infections are the most problematic in the immediate postoperative period. Most centers administer empiric antibiotics at the time of transplant and adjust these once results of intraoperative tracheal or bronchial aspirates are available [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chest radiographs of potential donors should be screened for any evidence of active or prior Mycobacterial tuberculosis infection, which would exclude the patient as a transplant donor. Although transmission of M tuberculosis from donors has been reported in the absence of chest x-ray findings, more extensive testing for M tuberculosis is not feasible as it would delay organ procurement [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential donors should be screened for HIV, hepatitis C, hepatitis B surface antigen, and hepatitis B core antibody positivity. Donors with hepatitis C should generally be excluded unless they are being transplanted into a recipient who is hepatitis C positive [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/17\">",
"     17",
"    </a>",
"    ]. Although the data in lung transplant are limited, extrapolation of data from renal transplant recipients suggest that while infection with a different strain of hepatitis C may occur, this does not substantially affect outcomes among recipients with prior hepatitis C infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31289?source=see_link\">",
"     \"Hepatitis C virus infection and renal transplantation\"",
"    </a>",
"    .) The risk of virus transmission in the setting of hepatitis B core antibody positivity, but surface antigen negativity, is low.",
"   </p>",
"   <p>",
"    When feasible, lungs from a CMV positive donor should not be given to a CMV negative recipient, although routine prophylaxis against CMV infection has reduced the morbidity and mortality associated with this infection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/17\">",
"     17",
"    </a>",
"    ]. Adenovirus transmission may lead to a poor outcome, so we prefer to avoid lungs with known infection. Parvovirus B19 transmission has lead to red cell aplasia in the recipient, but this was treatable with intravenous immunoglobulin [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/17\">",
"     17",
"    </a>",
"    ]. Donors with herpes viruses 6-8 simplex and varicella may be used with caution [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Ex vivo lung perfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications such as pulmonary edema, contusions, and vascular thrombosis have typically rendered donor lungs unacceptable for transplantation, thereby reducing the supply of donor lungs. Efforts to improve the quality, and therefore the quantity, of lungs available for transplantation are ongoing. Ex vivo lung perfusion (EVLP, also known as ex vivo reconditioning) is being explored as a way to increase the number of acceptable lungs [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/37-41\">",
"     37-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acellular, normothermic EVLP was assessed as a method to identify lungs that might be acceptable for transplantation, despite an initial assessment that they were unsuitable [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/37\">",
"     37",
"    </a>",
"    ]. High risk lungs from 23 donors underwent EVLP with Steen solution (buffered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    , extracellular type) for four hours during lung protective ventilation with an inspired oxygen fraction of 21 percent, after which lungs from 20 of the donors were deemed acceptable and were transplanted. Outcomes among recipients of EVLP lungs were compared with 116 lung transplants performed with lungs that were acceptable under conventional criteria. The rates of primary graft dysfunction at 72 hours were 15 percent in the EVLP group and 30 percent in the conventional criteria group. Thirty day mortality, hospital length of stay, bronchial complications, and duration of mechanical ventilation were not different between the groups. In a follow-up to this study, the first 50 lung transplants from 58 EVLP procedures achieved a one year survival of 87 percent compared with 86 percent of 267 transplants in the control group that met ideal donor criteria and did not undergo EVLP [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a separate study using an extracorporeal membrane oxygenation circuit and a hypertonic solution to dehydrate edematous lungs, six of nine initially unacceptable donor lungs were improved to acceptable condition and transplanted [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/38\">",
"     38",
"    </a>",
"    ]. Three month survival for all six recipients was 100 percent. At 24 months, four of the six were alive and healthy. Of the two that died, one died from sepsis after 95 days, the other from rejection at 9 months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DONOR MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Care of the organ donor starts before the declaration of brain death. The general principles of intensive care medicine apply to the management of the organ donor. Active donor management appears to improve the retrieval rate and the United Network for Organ Sharing (UNOS) has published guidelines for donor management (",
"    <a class=\"graphic graphic_table graphicRef54028 \" href=\"UTD.htm?18/41/19101\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/18,42-44\">",
"     18,42-44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cardiovascular compromise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain death often results in two phases of response by the cardiovascular system [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/45\">",
"     45",
"    </a>",
"    ]. The initial response is a hypertensive crisis due to a massive sympathetic discharge following brain death. This is followed by a hypotensive period that results from multiple factors, including hypovolemia, cardiac dysfunction, and vasodilation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/42\">",
"     42",
"    </a>",
"    ]. Currently, there is no widely accepted intervention to prevent the detrimental effects of this sympathetic storm, and management thus focuses on maintaining normovolemia, optimizing cardiac output, and blood pressure support.",
"   </p>",
"   <p>",
"    Echocardiography should be performed promptly for all potential donors. If the ejection fraction is estimated at less than 45 percent, or the patient is already on high dose inotropic support, placement of a pulmonary artery catheter should be considered to guide further therapy. The precise timing of echocardiography is currently controversial. It appears that the most important echocardiographic information is obtained once normovolemia has been achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/46\">",
"     46",
"    </a>",
"    ]. Therefore, it is reasonable to repeat the echocardiogram after volume repletion, if the first study was performed when the donor was hypovolemic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Volume repletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypotension is a frequent problem after brain death and can adversely affect potential organ donation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/47\">",
"     47",
"    </a>",
"    ]. Intravenous fluids should be used to bring the mean arterial pressure to 60 mmHg and the central venous pressure (CVP) to 6 to 8 mmHg or pulmonary capillary wedge pressure (PCWP) to 8 to 12 mmHg; more intense fluid resuscitation may improve renal function, but worsen gas exchange. We prefer colloids to crystalloids, though data confirming this is lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/48\">",
"     48",
"    </a>",
"    ]. Packed red blood cells should be used as the fluid of choice until anemia is corrected to a goal hemoglobin of approximately 10 mg per dL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=see_link\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=see_link\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Electrolyte balance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful attention should be paid to maintaining normal electrolyte levels. According to the UNOS guidelines, serum sodium should be maintained below 150",
"    <span class=\"nowrap\">",
"     mEq/dL",
"    </span>",
"    and potassium greater than 4",
"    <span class=\"nowrap\">",
"     mEq/dL",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef54028 \" href=\"UTD.htm?18/41/19101\">",
"     table 3",
"    </a>",
"    ). If serum sodium is elevated, the patient should be evaluated for central diabetes insipidus, which may result from traumatic brain injury. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Hormonal therapy'",
"    </a>",
"    below.) Acidosis should be corrected to a pH greater than 7.2 with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    and mild hyperventilation to pCO",
"    <sub>",
"     2",
"    </sub>",
"    of 30 to 35 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal strategy for mechanical ventilation of the donor is not known. Traditionally, tidal volumes of 8 to 15",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    and a positive end expiratory pressure (PEEP) of 5 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O have been used [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/49\">",
"     49",
"    </a>",
"    ]. However, many intensivists involved in lung transplantation strongly prefer lung protective ventilation, also known as low tidal volume ventilation, due to the benefits noted among patients with acute respiratory distress syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link&amp;anchor=H2#H2\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\", section on 'Low tidal volume ventilation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16182?source=see_link&amp;anchor=H2#H2\">",
"     \"Ventilator-associated lung injury\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of lung protective ventilation of potential organ donors on the number of lungs eligible for transplantation was assessed in a multicenter, randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/50\">",
"     50",
"    </a>",
"    ]. Potential donors were randomly assigned to conventional ventilation (tidal volumes 10 to 12",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of predicted body weight and PEEP of 3 to 5 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O) or protective ventilation (tidal volume 6 to 8",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of predicted body weight and PEEP of 8 to 10 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O) for a six hour observation period. In both groups, the respiratory rate was adjusted to obtain an arterial partial pressure of carbon dioxide (PaCO",
"    <sub>",
"     2",
"    </sub>",
"    ) of 40 to 45 mmHg. Thirty-two patients (54 percent) in the conventional ventilation group and 56 (95 percent) in the protective strategy group met lung donor eligibility criteria. Six month survival rates of lung transplant recipients did not differ between the two groups. Thus, if overall hemodynamic and acid-base status will allow, a low tidal volume ventilation strategy for potential lung donors appears to substantially increase the proportion of lungs that are acceptable for transplantation.",
"   </p>",
"   <p>",
"    Peak airway pressures should be maintained below 30 cm of water pressure. The critical care literature supports keeping the plateau (static) airway pressure below 25 to 30 cm water pressure to reduce lung injury. If plateau pressures are difficult to obtain, the peak pressure can be followed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13336?source=see_link\">",
"     \"Overview of mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measures to prevent ventilator associated pneumonia should be employed, including elevation of the head of the bed to 30 degrees, if blood pressure is adequate. Additional measures to prevent ventilator associated pneumonia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/1/34840?source=see_link&amp;anchor=H10#H10\">",
"     \"Infections and antimicrobial resistance in the intensive care unit\", section on 'Ventilator associated pneumonia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Hormonal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain death is associated with endocrine and metabolic dysfunction, and it is hypothesized that these changes may affect graft survival. Interventions to address these abnormalities include glucocorticoid, thyroxine, insulin, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5511?source=see_link\">",
"     vasopressin",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef54028 \" href=\"UTD.htm?18/41/19101\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/47,51,52\">",
"     47,51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a lack of consensus about when hormonal therapies should be initiated. Some experts recommend using them only in hemodynamically compromised donors, while others recommend broad use in most donors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/49\">",
"     49",
"    </a>",
"    ]. Generally,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5511?source=see_link\">",
"     vasopressin",
"    </a>",
"    is restricted to donors with hemodynamic compromise or with excessive urinary output. Some patients with traumatic brain injury develop diabetes insipidus, which is manifest by high urinary output &gt;1000",
"    <span class=\"nowrap\">",
"     mL/hour.",
"    </span>",
"    This may require specific treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    or vasopressin to maintain urinary output at 100 to 200",
"    <span class=\"nowrap\">",
"     mL/hour.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/31/505?source=see_link\">",
"     \"Treatment of central diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Glucocorticoids are often given prior to organ retrieval to optimize donor lung function, even if other hormonal agents have not been used [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/44,52\">",
"     44,52",
"    </a>",
"    ]. In addition, adrenal insufficiency after brain death has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/53\">",
"     53",
"    </a>",
"    ]. The typical dose is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    15",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    as an intravenous infusion.",
"   </p>",
"   <p>",
"    Glycemic control should also be maintained with an insulin drip",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a dextrose-containing solution, aiming for a blood glucose of 120 to 180",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and the avoidance of hypoglycemia during intensive insulin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Donor genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gene expression microarray technology has been used to find molecular markers that predict primary graft dysfunction (PGD) in transplant recipients. In a case-control study, gene microarrays of 10 donor lungs that developed PGD were compared with 16 controls with a favorable outcome; four upregulated genes, ATP11B, FGFR2, EGLN1, and MCPH1, were associated with development of PGD [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/54\">",
"     54",
"    </a>",
"    ]. Such biologic signatures may in the future supplement clinical criteria used at the pre-implantation evaluation and selection stage to predict post transplant complications, such as primary graft dysfunction, and help guide therapy in the immediate post transplant period.",
"   </p>",
"   <p>",
"    Gene therapy is also being investigated as a potential strategy to increase the number of donor lungs. Injured human lungs that were considered to be unsuitable for clinical use were treated with adenoviral mediated human IL-10 gene therapy. After preservation ex-vivo at body temperature, the IL-10 treated lungs showed reduced markers of inflammation and improved function (PaO",
"    <sub>",
"     2",
"    </sub>",
"    and pulmonary vascular resistance) compared with control untreated lungs [",
"    <a class=\"abstract\" href=\"UTD.htm?12/8/12425/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of transplanted lungs are donated after brain death, although a small portion are donated after cardiac death. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Donation after brain death'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The experience with lung donation after cardiac death (DCD) is increasing, and some studies show equivalent long-term outcomes compared with those of donation after brain death. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Donation after cardiac death'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ideal donors for lung transplant are less than 55 years of age, have smoked less than 20 pack years, have a normal chest radiograph and near normal gas exchange, absence of chest trauma or prior cardiothoracic surgery, and absence of known aspiration, sepsis or purulent respiratory secretions. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Ideal donor criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several retrospective series have examined recipient outcomes after use of donor lungs that do not meet ideal donor criteria and have found that outcomes for \"expanded\" donor criteria are only slightly worse than those for \"ideal\" organs. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Expanded donor criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ideally, the donor should have a PaO",
"      <sub>",
"       2",
"      </sub>",
"      &gt;300 mmHg on FiO",
"      <sub>",
"       2",
"      </sub>",
"      = 1.0, PEEP = 5 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O. When donor lungs are less than ideal (eg. &nbsp;PaO",
"      <sub>",
"       2",
"      </sub>",
"      :FiO",
"      <sub>",
"       2",
"      </sub>",
"      &lt;300 mmHg, radiographic pulmonary edema, DCD Maastricht score III or IV), several hours of normothermic ex vivo lung perfusion (EVLP) may allow safe use of these lungs. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Donation after cardiac death'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Donor selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main concern about using lungs from donors who have a tobacco smoking history of greater than 20 pack years is the possibility of transmission of bronchogenic cancer to the recipient. Usually, significant COPD can be detected by a history of respiratory symptoms, abnormality of chest radiograph and abnormal ventilator mechanics. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Smoking'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Malignancy is generally an absolute contraindication for organ donation, unless an adequate disease free interval has elapsed or the malignancy is of extremely low potential for metastasis (eg, carcinoma in situ of the cervix or some low grade nonmelanoma skin cancers). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Malignancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Brain death is associated with metabolic and endocrine dysfunction. Addressing abnormalities in thyroid, glucocorticoid,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5511?source=see_link\">",
"       vasopressin",
"      </a>",
"      , and insulin may improve donor organ viability. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Hormonal therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/1\">",
"      Wijdicks EF. The diagnosis of brain death. N Engl J Med 2001; 344:1215.",
"     </a>",
"    </li>",
"    <li>",
"     Medicare and Medicaid Programs; Conditions for Coverage for Organ Procurement Organizations (OPOs); Final Rule. Services, DoHaH (Ed), Federal Register May 31, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/3\">",
"      Kootstra G. Statement on non-heart-beating donor programs. Transplant Proc 1995; 27:2965.",
"     </a>",
"    </li>",
"    <li>",
"     www.unos.org/SharedContentDocuments/Policy-Notice-March-2007-BOD-Meeting(a)(1).pdf - 2008-03-18 (Accessed on January 01, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/5\">",
"      Bernat JL, Capron AM, Bleck TP, et al. The circulatory-respiratory determination of death in organ donation. Crit Care Med 2010; 38:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/6\">",
"      Steen S, Sj&ouml;berg T, Pierre L, et al. Transplantation of lungs from a non-heart-beating donor. Lancet 2001; 357:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/7\">",
"      Bernat JL, D'Alessandro AM, Port FK, et al. Report of a National Conference on Donation after cardiac death. Am J Transplant 2006; 6:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/8\">",
"      Ethics Committee, American College of Critical Care Medicine, Society of Critical Care Medicine. Recommendations for nonheartbeating organ donation. A position paper by the Ethics Committee, American College of Critical Care Medicine, Society of Critical Care Medicine. Crit Care Med 2001; 29:1826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/9\">",
"      Guidelines for the determination of death. Report of the medical consultants on the diagnosis of death to the President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. JAMA 1981; 246:2184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/10\">",
"      Robertson JA. The dead donor rule. Hastings Cent Rep 1999; 29:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/11\">",
"      De Oliveira NC, Osaki S, Maloney JD, et al. Lung transplantation with donation after cardiac death donors: long-term follow-up in a single center. J Thorac Cardiovasc Surg 2010; 139:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/12\">",
"      Eberlein M, Permutt S, Chahla MF, et al. Lung size mismatch in bilateral lung transplantation is associated with allograft function and bronchiolitis obliterans syndrome. Chest 2012; 141:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/13\">",
"      Eberlein M, Reed RM, Permutt S, et al. Parameters of donor-recipient size mismatch and survival after bilateral lung transplantation. J Heart Lung Transplant 2012; 31:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/14\">",
"      Mason DP, Batizy LH, Wu J, et al. Matching donor to recipient in lung transplantation: How much does size matter? J Thorac Cardiovasc Surg 2009; 137:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/15\">",
"      Shigemura N, Bermudez C, Hattler BG, et al. Impact of graft volume reduction for oversized grafts after lung transplantation on outcome in recipients with end-stage restrictive pulmonary diseases. J Heart Lung Transplant 2009; 28:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/16\">",
"      Bhorade SM, Vigneswaran W, McCabe MA, Garrity ER. Liberalization of donor criteria may expand the donor pool without adverse consequence in lung transplantation. J Heart Lung Transplant 2000; 19:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/17\">",
"      Garrity ER Jr, Boettcher H, Gabbay E. Donor infection: an opinion on lung donor utilization. J Heart Lung Transplant 2005; 24:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/18\">",
"      Rosendale JD, Chabalewski FL, McBride MA, et al. Increased transplanted organs from the use of a standardized donor management protocol. Am J Transplant 2002; 2:761.",
"     </a>",
"    </li>",
"    <li>",
"     UNOS Allocation of Deceased Kidneys Policy, 2007 file://www.unos.org/policiesandbylaws/policies.asp?fromPage=Policy.31 (Accessed on February 11, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/20\">",
"      Whiting D, Banerji A, Ross D, et al. Liberalization of donor criteria in lung transplantation. Am Surg 2003; 69:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/21\">",
"      Pierre AF, Sekine Y, Hutcheon MA, et al. Marginal donor lungs: a reassessment. J Thorac Cardiovasc Surg 2002; 123:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/22\">",
"      D'Armini AM, Boffini M, Zanotti G, et al. \"Twinning procedure\" in lung transplantation: influence of graft ischemia on survival and incidence of complications. Transplant Proc 2004; 36:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/23\">",
"      Aigner C, Winkler G, Jaksch P, et al. Extended donor criteria for lung transplantation--a clinical reality. Eur J Cardiothorac Surg 2005; 27:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/24\">",
"      Lardinois D, Banysch M, Korom S, et al. Extended donor lungs: eleven years experience in a consecutive series. Eur J Cardiothorac Surg 2005; 27:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/25\">",
"      Reyes KG, Mason DP, Thuita L, et al. Guidelines for donor lung selection: time for revision? Ann Thorac Surg 2010; 89:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/26\">",
"      Orens JB, Boehler A, de Perrot M, et al. A review of lung transplant donor acceptability criteria. J Heart Lung Transplant 2003; 22:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/27\">",
"      Salerno CT, Burdine J, Perry EH, et al. Donor-derived antibodies and hemolysis after ABO-compatible but nonidentical heart-lung and lung transplantation. Transplantation 1998; 65:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/28\">",
"      Yu NC, Haug MT 3rd, Khan SU, et al. Does the donor-recipient ABO blood group compatibility status predict subsequent lung transplantation outcomes? J Heart Lung Transplant 1999; 18:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/29\">",
"      Banner NR, Rose ML, Cummins D, et al. Management of an ABO-incompatible lung transplant. Am J Transplant 2004; 4:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/30\">",
"      Angel LF, Levine DJ, Restrepo MI, et al. Impact of a lung transplantation donor-management protocol on lung donation and recipient outcomes. Am J Respir Crit Care Med 2006; 174:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/31\">",
"      de Perrot M, Wigle DA, Pierre AF, et al. Bronchogenic carcinoma after solid organ transplantation. Ann Thorac Surg 2003; 75:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/32\">",
"      Berman M, Goldsmith K, Jenkins D, et al. Comparison of outcomes from smoking and nonsmoking donors: thirteen-year experience. Ann Thorac Surg 2010; 90:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/33\">",
"      Bonser RS, Taylor R, Collett D, et al. Effect of donor smoking on survival after lung transplantation: a cohort study of a prospective registry. Lancet 2012; 380:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/34\">",
"      Healey PJ, Davis CL. Transmission of tumours by transplantation. Lancet 1998; 352:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/35\">",
"      Fishman JA, Greenwald MA, Kuehnert MJ. Enhancing transplant safety: a new era in the microbiologic evaluation of organ donors? Am J Transplant 2007; 7:2652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/36\">",
"      Ridgeway AL, Warner GS, Phillips P, et al. Transmission of Mycobacterium tuberculosis to recipients of single lung transplants from the same donor. Am J Respir Crit Care Med 1996; 153:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/37\">",
"      Cypel M, Yeung JC, Liu M, et al. Normothermic ex vivo lung perfusion in clinical lung transplantation. N Engl J Med 2011; 364:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/38\">",
"      Ingemansson R, Eyjolfsson A, Mared L, et al. Clinical transplantation of initially rejected donor lungs after reconditioning ex vivo. Ann Thorac Surg 2009; 87:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/39\">",
"      Zych B, Popov AF, Stavri G, et al. Early outcomes of bilateral sequential single lung transplantation after ex-vivo lung evaluation and reconditioning. J Heart Lung Transplant 2012; 31:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/40\">",
"      Wallinder A, Ricksten SE, Hansson C, et al. Transplantation of initially rejected donor lungs after ex vivo lung perfusion. J Thorac Cardiovasc Surg 2012; 144:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/41\">",
"      Cypel M, Yeung JC, Machuca T, et al. Experience with the first 50 ex vivo lung perfusions in clinical transplantation. J Thorac Cardiovasc Surg 2012; 144:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/42\">",
"      Wood KE, Becker BN, McCartney JG, et al. Care of the potential organ donor. N Engl J Med 2004; 351:2730.",
"     </a>",
"    </li>",
"    <li>",
"     UNOS. Critical Pathway for the Organ Donor file://www.unos.org/resources/donorManagement.asp?index=2 (Accessed on February 03, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/44\">",
"      Venkateswaran RV, Patchell VB, Wilson IC, et al. Early donor management increases the retrieval rate of lungs for transplantation. Ann Thorac Surg 2008; 85:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/45\">",
"      Avlonitis VS, Wigfield CH, Kirby JA, Dark JH. The hemodynamic mechanisms of lung injury and systemic inflammatory response following brain death in the transplant donor. Am J Transplant 2005; 5:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/46\">",
"      Ullah S, Zabala L, Watkins B, Schmitz ML. Cardiac organ donor management. Perfusion 2006; 21:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/47\">",
"      Salim A, Martin M, Brown C, et al. The effect of a protocol of aggressive donor management: Implications for the national organ donor shortage. J Trauma 2006; 61:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/48\">",
"      SAFE Study Investigators, Australian and New Zealand Intensive Care Society Clinical Trials Group, Australian Red Cross Blood Service, et al. Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med 2007; 357:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/49\">",
"      Rosengard BR, Feng S, Alfrey EJ, et al. Report of the Crystal City meeting to maximize the use of organs recovered from the cadaver donor. Am J Transplant 2002; 2:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/50\">",
"      Mascia L, Pasero D, Slutsky AS, et al. Effect of a lung protective strategy for organ donors on eligibility and availability of lungs for transplantation: a randomized controlled trial. JAMA 2010; 304:2620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/51\">",
"      Rosendale JD, Kauffman HM, McBride MA, et al. Aggressive pharmacologic donor management results in more transplanted organs. Transplantation 2003; 75:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/52\">",
"      Abdelnour T, Rieke S. Relationship of hormonal resuscitation therapy and central venous pressure on increasing organs for transplant. J Heart Lung Transplant 2009; 28:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/53\">",
"      Dimopoulou I, Tsagarakis S, Anthi A, et al. High prevalence of decreased cortisol reserve in brain-dead potential organ donors. Crit Care Med 2003; 31:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/54\">",
"      Anraku M, Cameron MJ, Waddell TK, et al. Impact of human donor lung gene expression profiles on survival after lung transplantation: a case-control study. Am J Transplant 2008; 8:2140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/8/12425/abstract/55\">",
"      Cypel M, Liu M, Rubacha M, et al. Functional repair of human donor lungs by IL-10 gene therapy. Sci Transl Med 2009; 1:4ra9.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4664 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-199.231.185.123-23AA9155C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_8_12425=[""].join("\n");
var outline_f12_8_12425=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DONATION AFTER BRAIN DEATH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DONATION AFTER CARDIAC DEATH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12653407\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DONOR SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Size matching",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Ideal donor criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Expanded donor criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Advanced donor age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - ABO compatibility",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Abnormal chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H103242957\">",
"      - Cytomegalovirus antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Low PaO2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H103242891\">",
"      - Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Smoking",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Malignancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Donor infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Ex vivo lung perfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DONOR MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cardiovascular compromise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Volume repletion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Electrolyte balance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Hormonal therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Donor genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4664\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4664|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/34/23083\" title=\"table 1\">",
"      Lung transplant donor criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/34/41515\" title=\"table 2\">",
"      Donor infections limit lung tx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/41/19101\" title=\"table 3\">",
"      Lung transplant donor management",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=related_link\">",
"      Chronic lung transplant rejection: Bronchiolitis obliterans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30761?source=related_link\">",
"      Diagnosis of brain death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31289?source=related_link\">",
"      Hepatitis C virus infection and renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/1/34840?source=related_link\">",
"      Infections and antimicrobial resistance in the intensive care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3480?source=related_link\">",
"      Lung transplantation: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31192?source=related_link\">",
"      Lung transplantation: Disease-based choice of procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5640?source=related_link\">",
"      Lung transplantation: Donor lung preservation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26953?source=related_link\">",
"      Lung transplantation: General guidelines for recipient selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=related_link\">",
"      Mechanical ventilation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13336?source=related_link\">",
"      Overview of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11434?source=related_link\">",
"      Overview of the management of postoperative pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=related_link\">",
"      Shock in adults: Types, presentation, and diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13113?source=related_link\">",
"      Strategies to reduce postoperative pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/31/505?source=related_link\">",
"      Treatment of central diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16182?source=related_link\">",
"      Ventilator-associated lung injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_8_12426="Fallopian tube mucosal proliferations";
var content_f12_8_12426=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F86933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F86933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Fallopian tube mucosal proliferations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 391px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Discrete mucosal proliferations seen in the tube that are not directly connected to serous carcinoma.",
"    <br/>",
"    (A) A secretory cell outgrowth (boxed area); (B) note the lack of PAX2 immunostaining, suggesting dysregulation of expression. The inset contrast normal epithelium (upper) and that lacking PAX2 expression (lower).",
"    <br/>",
"    (C) A discrete papillary proliferation which at higher power (in D) exhibits both secretory and ciliated differentiation. These are uncommon and bear a resemblance to low-grade serous tumors seen in the ovary.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_8_12426=[""].join("\n");
var outline_f12_8_12426=null;
var title_f12_8_12427="Common causes LGI bleeding";
var content_f12_8_12427=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F58308&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F58308&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common causes of lower gastrointestinal bleeding",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Anatomic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diverticulosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Vascular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Angiodysplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ischemic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiation-induced telangiectasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Inflammatory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infectious",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inflammatory bowel disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neoplastic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyp",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Others",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemorrhoid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ulcer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Post biopsy or polypectomy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_8_12427=[""].join("\n");
var outline_f12_8_12427=null;
var title_f12_8_12428="Developmental models ASD";
var content_f12_8_12428=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Examples of developmental approaches for children with autism spectrum disorders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"25%\">",
"     </colgroup>",
"     <colgroup width=\"75%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Model",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Denver model",
"       </td>",
"       <td>",
"        Uses play, interpersonal relationships, and activities to remediate core deficits in imitation, emotion sharing, theory of mind, and social perception",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Early Start Denver Model",
"       </td>",
"       <td>",
"        Integrative program that uses a combination of developmental and relationship-based approaches and intensive applied behavior analytic (ABA) programming; includes parents as therapists",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Developmental Individual Difference (DIR), also called Floortime",
"       </td>",
"       <td>",
"        Focuses on \"floor time\" play sessions and other strategies to enhance relationships and social interactions to facilitate emotional and cognitive development; seeks to address deficits in auditory processing, language, motor planning and sequencing, sensory modulation, and visual-spatial processing",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Milieu therapy",
"       </td>",
"       <td>",
"        Focuses on teaching children new communication skills and behaviors in their natural environments",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        More Than Words&reg;",
"       </td>",
"       <td>",
"        Family-focused program that provides parents with practical tools to help their child communicate",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Relationship-development intervention (RDI)",
"       </td>",
"       <td>",
"        Focuses on activities that elicit interactive behaviors to engage the child in a social relationship; utilizes play-based scenarios that draw out social behaviors and secondarily motivate the child to be more social",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Responsive teaching",
"       </td>",
"       <td>",
"        Development curriculum implemented by parents during routine interactions in the child's natural environment to address cognitive, communication, and social needs",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Myers SM, Johnson CP. American Academy of Pediatrics Council on Children with Disabilities. Management of Children with Autism Spectrum Disorders. Pediatrics 2007; 120:1162.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_8_12428=[""].join("\n");
var outline_f12_8_12428=null;
var title_f12_8_12429="Citrate and aluminum absorption";
var content_f12_8_12429=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F55777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F55777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 510px\">",
"   <div class=\"ttl\">",
"    Increase in urinary aluminum excretion with administration of aluminum hydroxide, sodium bicarbonate, and citrate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 490px; height: 251px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Increase in urinary aluminum excretion in subjects on a control diet and those given aluminum hydroxide (AlOH) alone or with sodium bicarbonate or sodium citrate. Aluminum excretion rose markedly in the last group due to increased intestinal absorption.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Walker JA, Sherman RA, Cody RF. Arch Intern Med 1990; 150:2037.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_8_12429=[""].join("\n");
var outline_f12_8_12429=null;
var title_f12_8_12430="Leucine degradation pathway and branched-chain organic acidemias";
var content_f12_8_12430=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65861&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65861&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Pathway of leucine degradation and branched-chain organic acidemias",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 426px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IVA: isovaleric acidemia; 3-MCG: 3-methylcrotonylglycinuria; 3-MGA: 3-methylglutaconic aciduria.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_8_12430=[""].join("\n");
var outline_f12_8_12430=null;
var title_f12_8_12431="Dose response PEG rHuMGDF A";
var content_f12_8_12431=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F59564%7EHEME%2F72350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F59564%7EHEME%2F72350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Response to thrombopoietin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 439px; height: 303px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dose-response of daily subcutaneous injections of PEG-recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) for 28 days on the peripheral platelet count in baboons. The daily doses were 0.05 (red), 0.10 (blue), 0.50 (black), and 2.50 (green) &micro;g/kg. The peripheral platelet count increased incrementally in a log-linear dose-response manner.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Harker, LA, Marzec, UM, Hunt, P, et al, Blood 1996; 88:511.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Response to thrombopoietin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 379px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The fold increase in platelet count on day 14 is shown here versus the logarithm of the administered dose of thrombopoietin. The platelet counts returned to baseline values upon discontinuation of therapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Harker, LA, Marzec, UM, Hunt, P, et al, Blood 1996; 88:511.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_8_12431=[""].join("\n");
var outline_f12_8_12431=null;
